0001641172-25-000862 | 10-K | XBRL Viewer

Cover - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
Cover - USD ($) $ / shares in Units, $ in Millions	Dec. 31, 2024	Mar. 20, 2025	Jun. 28, 2024
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2024
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-41184
Entity Registrant Name	ZYVERSA THERAPEUTICS, INC.
Entity Central Index Key	0001859007
Entity Tax Identification Number	86-2685744
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2200 N. Commerce Parkway
Entity Address, Address Line Two	Suite 208
Entity Address, City or Town	Weston
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33326
City Area Code	(754)
Local Phone Number	231-1688
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	ZVSA
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 3.1
Entity Common Stock, Shares Outstanding		2,568,191
Documents Incorporated by Reference [Text Block]	None
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Listing, Par Value Per Share	$ 0.0001
Auditor Firm ID	688
Auditor Name	Marcum LLP
Auditor Location	New York, NY

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 3 – Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements have been derived from the accounting records of the Company and its consolidated subsidiaries. All significant intercompany balances have been eliminated in the consolidated financial statements. The consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and pursuant to the accounting rules and regulations of the United States Securities and Exchange Commission (“SEC”).

On December 4, 2023, the Company effected a reverse stock split of its common stock at a ratio of 1-for-35 (the “2023 Reverse Split”). Upon the effectiveness of the 2023 Reverse Split, every 35 issued shares of common stock were reclassified and combined into one share of common stock. In addition, the number of shares of common stock issuable upon the exercise of the Company’s equity awards, convertible securities and warrants was proportionally decreased, and the corresponding conversion price or exercise price was proportionally increased. No fractional shares were issued as a result of the 2023 Reverse Split.

On April 25, 2024, the Company effected a reverse stock split of its common stock at a ratio of 1-for-10 (the “2024 Reverse Split”). Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into one share of common stock. In addition, the number of shares of common stock issuable upon the exercise of the Company’s equity awards, convertible securities and warrants was proportionally decreased, and the corresponding conversion price or exercise price was proportionally increased. No fractional shares were issued as a result of the 2024 Reverse Split.

Accordingly, all share and per share amounts for all periods presented in these financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the 2023 Reverse Split and the 2024 Reverse Split and adjustment of the conversion price or exercise price of each outstanding equity award, convertible security and warrant as if the transaction had occurred as of the beginning of the earliest period presented. See Note 9 – Stockholders’ Permanent and Temporary Equity – Reverse Stock Split.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Use of Estimates

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, share based compensation and acquired intangible assets, as well as establishment of valuation allowances for deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements. As of December 31, 2024 and 2023, the Company had no cash equivalents.

The Company has cash deposits which, at times, may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. See Note 1 – Risks and Uncertainties.

Business Combination

In applying the acquisition method of accounting for business combinations, amounts assigned to identifiable assets and liabilities acquired were based on estimated fair values as of the date of acquisition, with the remainder recorded as goodwill. Intangible assets are initially valued at fair value using generally accepted valuation methods appropriate for the type of intangible asset. In-process research and development (IPR&D) acquired in a business combination is capitalized as an indefinite-lived intangible asset until regulatory approval is obtained, at which time it is accounted for as a definite-lived asset and amortized over its estimated useful life, or discontinuation, at which point the intangible asset will be written off.

Long-Lived Assets and Goodwill

The Company accounts for long-lived assets in accordance with the provisions of ASC 360-10-35, Property, Plant and Equipment, Impairment or Disposal of Long-lived Assets. This accounting standard requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company intends to perform its annual impairment testing during the fourth quarter of each year.

The Company accounts for goodwill and intangible assets in accordance with ASC 350, Intangibles – Goodwill and Other. Goodwill represents the excess of the purchase price of an entity over the estimated fair value of the assets acquired and liabilities assumed. ASC 350 requires that goodwill and other intangibles with indefinite lives be tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value of an asset has decreased below its carrying value.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

In determining whether a quantitative assessment is required, the Company will evaluate relevant events or circumstances to determine whether it is more likely than not that the fair value of a reporting unit or an indefinite-lived intangible asset is less than its carrying amount. If, after performing the qualitative assessment, an entity concludes that it is more likely than not that the fair value of a reporting unit or an indefinite-lived intangible asset is less than its carrying amount, the entity would perform the quantitative impairment test described in ASC 350. However, if, after applying the qualitative assessment, the entity concludes that it is not more than likely that the fair value is less than the carrying amount, the quantitative impairment test is not required. The Company bases these assumptions on its historical data and experience, industry projections, micro and macro general economic condition projections, and its expectations.

Equipment, Net

Equipment is stated at cost, net of accumulated depreciation, which is recorded commencing at the in-service date using the straight- line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which is 5 years. For the years ended on December 31, 2024 and 2023, equipment consisted of $52,000 of medical equipment, placed in service on September 1, 2019, less accumulated depreciation of $52,000 and $45,067 as of December 31, 2024 and 2023, respectively. During the years ended December 31, 2024 and 2023, the Company recognized depreciation expense of $6,933 and $10,400, respectively. Depreciation expense was included in general and administrative expenses in the statements of operations for all periods.

Deferred Offering Costs

Deferred offering costs, which primarily consist of direct, incremental professional fees incurred in connection with a debt or equity financing, are capitalized as deferred offering costs (a non-current asset) on the balance sheet. Once the financing closes, the Company reclassifies such costs as either discounts to notes payable or as a reduction of proceeds received from equity transactions so that such costs are recorded as a reduction of additional paid-in capital. If the completion of a contemplated financing was deemed to be no longer probable, the related deferred offering costs would be charged to general and administrative expense in the consolidated financial statements.

Fair Value of Financial Instruments

The Company measures the fair value of financial assets and liabilities based on ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 — quoted prices in active markets for identical assets or liabilities;

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable; and

Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).

The carrying amounts of the Company’s financial instruments, such as cash, accounts payable, accrued expenses, and deposits approximate fair values due to the short-term nature of these instruments.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Income Taxes

The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statements of operations in the period that includes the enactment date.

The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.

Research and Development

Research and development expenses are charged to operations as incurred.

Stock-Based Compensation

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.

Fair Value of Stock Options and Warrants

The Company has computed the fair value of stock options and warrants granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. Common stock is being valued using the market approach using the trading prices of the common stock on the Nasdaq Capital Market. The expected term used for options is the estimated period of time that options granted are expected to be outstanding. The expected term used for warrants is the contractual life. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” option grants. The Company did not have a public trading history for the common shares to support its historical volatility calculations until December 13, 2022. Accordingly, the Company is utilizing an expected volatility figure based on a review of the historical volatility of five comparable entities over a period of time equivalent to the expected life of the instrument being valued. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.

Net Loss Per Common Share

Basic net loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period, plus the weighted average number of pre-funded warrants outstanding where common stock is issuable for little or no consideration. Diluted net income per common share is computed by dividing net income by the weighted average number of common and dilutive common-equivalent shares outstanding during each period.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:

	2024		2023
	For the Years Ended
	December 31,
	2024		2023

Warrants ^[1]		1,747,093		903,274
Options		9,612		10,243
Series A convertible preferred stock		72		72
Series B convertible preferred stock		2,067		2,067
Total potentially dilutive shares		1,758,844		915,657

[1]

As part of the InflamaCORE, LLC license agreement, warrants to purchase 342 shares of common stock are to be issued upon the satisfaction of certain milestones and, accordingly, are not included in the amount currently reported. See Note 8 - Commitments and Contingencies - License Agreements for details.

Vendor Concentration

As of December 31, 2024 and 2023, accounts payable to one vendor accounted for 56% and 59%, respectively, of the accounts payable related to research and development. The Company relies on this vendor to perform critical research and development.

Segment Reporting

The Company operates and manages its business as one reportable and operating segment. All assets and operations are in the U.S. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.

Recently Adopted Accounting Pronouncements

In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segments Disclosures (Topic 280), which updates reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses on both an annual and interim basis. The guidance becomes effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. Since this new ASU addresses only disclosures, this ASU did not have any material effects on the Company’s financial condition, results of operations or cash flows.

Recently Issued Accounting Pronouncements

In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220 – 04). This update requires an entity to disclose more detailed information regarding expenses for the entity. The amendments require that at each interim and the annual reporting period, the entity must disclose amounts related to purchases of inventory, employee compensation, depreciation, and intangible asset amortization. Including the amounts, the entity is required to disclose and qualitative description of the amounts remaining in relevant expense captions, and to disclose the total amount of selling expenses and the definition of selling expenses. The amendments in this update should be applied prospectively to financial statements issued for reporting periods, and retrospectively to any prior periods presented in the financials. Although early adoption is permitted, the new guidance becomes effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Since this new ASU addresses only disclosures, the Company does not expect the adoption of this ASU to have any material effects on its financial condition, results of operations or cash flows.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Basis of Presentation and Principles of Consolidation

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Use of Estimates

Cash and Cash Equivalents

Business Combination

Long-Lived Assets and Goodwill

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Equipment, Net

Deferred Offering Costs

Fair Value of Financial Instruments

Level 1 — quoted prices in active markets for identical assets or liabilities;

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable; and

Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Income Taxes

The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.

Research and Development

Research and development expenses are charged to operations as incurred.

Stock-Based Compensation

Fair Value of Stock Options and Warrants

Net Loss Per Common Share

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:

	2024		2023
	For the Years Ended
	December 31,
	2024		2023

Warrants ^[1]		1,747,093		903,274
Options		9,612		10,243
Series A convertible preferred stock		72		72
Series B convertible preferred stock		2,067		2,067
Total potentially dilutive shares		1,758,844		915,657

[1]

Vendor Concentration

Segment Reporting

Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements

Schedule of Stock Options Granted (Details)	12 Months Ended
Schedule of Stock Options Granted (Details)	Dec. 31, 2023 $ / shares
Expected dividends	0.00%
Minimum [Member]
Fair value of common stock on date of grant	$ 152.50
Risk free interest rate	3.53%
Expected term (years)	5 years
Expected volatility	120.00%
Maximum [Member]
Fair value of common stock on date of grant	$ 791.00
Risk free interest rate	4.27%
Expected term (years)	6 years
Expected volatility	123.00%

Segment Reporting

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Segment Reporting

Note 10 – Segment Reporting

The Company has one operating and reporting segment (clinical stage biopharmaceutical), namely, the development of drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The chief operating decision maker (“CODM”), who is the Company’s chief executive officer, utilizes the Company’s financial information on an aggregate, consolidated basis for purposes of making operating decisions, allocating resources and assessing financial performance, as well as for making strategic operations decisions and managing the organization. The CODM is not regularly provided with disaggregated actual expense information, other than the actual expense information included in the consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total assets. The Company has not yet generated any revenue from product sales.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

+ Details

Schedule of Right of Use Assets and Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Operating cash flows used in operating activities	$ 8,656	$ 100,099
Operating leases
Weighted average remaining lease term		29 days
Weighted average discount rate		6.50%

Note Receivable (Details Narrative) - USD ($)	Jan. 30, 2024	Mar. 29, 2023	Feb. 28, 2023	Dec. 13, 2020	Feb. 20, 2023
Debt instrument interest rate					2.00%
License Agreement [Member] \| L&F Research LLC [Member] \| Waiver A [Member]
Cash payment		$ 648,421	$ 648,421
License Agreement [Member] \| L&F Research LLC [Member] \| Waiver B [Member]
Cash payment	$ 500,000		$ 500,000
L&F Note [Member]
Debt instrument face amount				$ 351,579
Debt instrument interest rate				1.17%
Prepay of note, description				L&F is required to immediately prepay the L&F Note and all accrued and unpaid interest on the L&F Note with the following: (a) 100% of the proceeds of the second $500,000 of milestone payments paid by ZyVersa to L&F pursuant to the terms of the license agreement (See Note 8 - Commitments and Contingencies), (b) 100% of the gross proceeds from the sale of common stock by L&F to ZyVersa pursuant to the terms of the Put Option (See Note 9 – Stockholders’ Permanent and Temporary Equity), (c) 100% of the gross proceeds in excess of $1.00 per share from the sale of ZyVersa common stock by L&F to any party other than ZyVersa and (d) proceeds received in connection with certain liquidation events as defined in the agreement. Commencing on December 13, 2021 and, so long as the principal amount of the L&F Note remains outstanding, on each December 13 through December 13, 2025, the Company will pay L&F an annual administrative fee equal to $6,000.
Milestone payments				$ 500,000
Administrative fee				$ 6,000

Schedule of Provision for Income Taxes Differs from Federal Statutory Rate (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Federal statutory rate	21.00%	21.00%
State tax rate, net of federal benefit	3.00%	3.80%
Permanent items	0.00%	(2.80%)
Stock-based compensation	(3.20%)	0.00%
Effect of change in state rate	0.20%	(0.10%)
Prior period adjustments and other	(1.30%)	0.00%
Change in valuation allowance	(19.80%)	(13.10%)
Other	0.00%	0.00%
Effective income tax rate	(0.10%)	8.80%

Business Organization, Nature of Operations and Risks and Uncertainties (Details Narrative)	Dec. 31, 2024 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash FDIC insured amount	$ 250,000

Schedule of Provision for Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Current tax benefit:
Federal
State		23,240
Current tax benefit		23,240
Deferred tax benefit:
Federal	(1,688,265)	(19,104,800)
State	(164,376)	(4,468,170)
Deferred tax benefit	(1,852,641)	(23,572,970)
Change in valuation allowance	1,859,386	14,093,900
Provision for income taxes	$ 6,745	$ (9,455,830)

Segment Reporting (Details Narrative)	12 Months Ended
Segment Reporting (Details Narrative)	Dec. 31, 2024 Segment
Segment Reporting [Abstract]
Number of operating and reporting segment	1

Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares

12 Months Ended

Dec. 31, 2024

Dec. 31, 2023

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

1,758,844

915,657

Warrant [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

^[1]

1,747,093

903,274

Share-Based Payment Arrangement, Option [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

9,612

10,243

Series A Convertible Preferred Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

Series B Convertible Preferred Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total potentially dilutive shares

2,067

[1]

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2024

Income Tax Disclosure [Abstract]

Schedule of Provision for Income Taxes

The provision for income taxes consists of the following (benefits) provisions:

Schedule of Provision for Income Taxes

	2024			2023
	For the Years Ended
	December 31,
	2024			2023

Current tax benefit:
Federal	$	-		$	-
State		-			23,240
Current tax benefit		-			23,240

Deferred tax benefit:
Federal		(1,688,265	)		(19,104,800	)
State		(164,376	)		(4,468,170	)
Deferred tax benefit		(1,852,641	)		(23,572,970	)
Change in valuation allowance		1,859,386			14,093,900
Provision for income taxes	$	6,745		$	(9,455,830	)

Schedule of Provision for Income Taxes Differs from Federal Statutory Rate

The provision for income taxes differs from the Federal statutory rate as follows:

	2024			2023
	For the Years Ended
	December 31,
	2024			2023

Federal statutory rate		21.0	%		21.0	%
State tax rate, net of federal benefit		3.0	%		3.8	%
Permanent items		0.0	%		(2.8	)%
Stock-based compensation		(3.2	)%		0.0	%
Effect of change in state rate		0.2	%		(0.1	)%
Prior period adjustments and other		(1.3	)%		0.0	%
Change in valuation allowance		(19.8	)%		(13.1	)%
Other		0.0	%		0.0	%
Effective income tax rate		(0.1	)%		8.8	%

Schedule of Deferred Tax Assets and Liabilities

Deferred tax assets and liabilities consist of the following:

	2024			2023
	As of December 31,
	2024			2023

Net operating loss carryforwards	$	12,544,318		$	9,974,075
Stock-based compensation expense		3,155,058			3,258,463
Capitalized research and development costs		1,753,207			2,182,104
Capitalized start-up costs		781,342			1,033,504
Capitalized licensing costs		609,669			647,489
Capitalized patents		392,691			351,721
Warrants		135,319			134,341
Accrued payroll		394,406			299,487
Contributions carryforward		2,878			2,857
Operating lease liability		-			2,151
Deferred tax assets		19,768,888			17,886,192
Valuation allowance		(15,953,288	)		(14,093,900	)
Deferred tax assets		3,815,600			3,792,292

Operating lease right-of-use asset		-			(1,948	)
In-process research and development		(4,667,259	)		(4,633,535	)
Fixed assets		-			(1,723	)
Deferred tax liabilities		(4,667,259	)		(4,637,206	)

Deferred tax assets, net	$	(851,659	)	$	(844,914	)

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2024	Dec. 31, 2023
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	2,508,198	405,212
Common stock, shares outstanding	2,508,191	402,205
Treasury stock shares	7	7
Series A Preferred Stock [Member]
Preferred stock, shares authorized	8,635	8,635
Preferred stock, shares issued	50	50
Preferred stock, shares outstanding	50	50
Series B Preferred Stock [Member]
Preferred stock, shares authorized	5,062	5,062
Preferred stock, shares issued	5,062	5,062
Preferred stock, shares outstanding	5,062	5,062

Note Receivable

12 Months Ended

Dec. 31, 2024

Note Receivable

Note Receivable

Note 5 – Note Receivable

On December 13, 2020, the Company and L&F Research LLC (“L&F”) entered into a promissory note agreement (“L&F Note Agreement”) whereby the Company agreed to accept a note receivable in the principal amount of $351,579 from L&F (“L&F Note”). The L&F Note bears interest at a rate of 1.17% per annum, payable annually, and matures on the earliest of (a) the date on which the Company demands payment of all amounts outstanding under the L&F Note following an event of default and (b) December 15, 2025. L&F is required to immediately prepay the L&F Note and all accrued and unpaid interest on the L&F Note with the following: (a) 100% of the proceeds of the second $500,000 of milestone payments paid by ZyVersa to L&F pursuant to the terms of the license agreement (See Note 8 - Commitments and Contingencies), (b) 100% of the gross proceeds from the sale of common stock by L&F to ZyVersa pursuant to the terms of the Put Option (See Note 9 – Stockholders’ Permanent and Temporary Equity), (c) 100% of the gross proceeds in excess of $1.00 per share from the sale of ZyVersa common stock by L&F to any party other than ZyVersa and (d) proceeds received in connection with certain liquidation events as defined in the agreement. Commencing on December 13, 2021 and, so long as the principal amount of the L&F Note remains outstanding, on each December 13 through December 13, 2025, the Company will pay L&F an annual administrative fee equal to $6,000.

The L&F Note was outstanding as of December 31, 2022 as the Company had not received payment from L&F of the amount due, nor had the Company made any required payments to L&F in connection with the license agreement described in Note 8 – Commitments and Contingencies, and such amount was recorded as a contra-liability against the milestone payments due to L&F in connection with the license agreement, which was included in accrued expenses and other current liabilities (see Note 6 – Accrued Expenses and other Current Liabilities). In recording the L&F Note receivable as a contra-liability, the Company considered the commercial substance, the intent of the parties and the overall contractual agreements between ZyVersa and L&F Research, which afford both parties the legal right to set-off the milestone liability owed by the Company to L&F Research with the L&F Note receivable to the Company. The Company determined that the amounts could be offset in the balance sheet because i) the amounts owed by and to the Company are determinable, ii) the Company has a legal right to set off the milestone liability owed to L&F Research by the amount of the L&F Note due to the Company, iii) the Company intends to set off the L&F Note receivable against the milestone liability, and iv) the set off right is enforceable by law.

On March 29, 2023, the Company paid the $648,421 of cash to L&F, thus meeting the conditions of Waiver A (see Note 8 – Commitments and Contingencies), which also had the effect of canceling the Note Receivable and the Put Option.

On January 30, 2024, the Company paid $500,000 of cash to L&F, thus meeting the conditions of Waiver B.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

Schedule of Right of Use Assets and Liabilities

A summary of the Company’s right-of-use assets and liabilities is as follows:

	2024		2023
	For the Years Ended
	December 31,
	2024		2023

Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows used in operating activities	$	8,656	$	100,099

Right-of-use assets obtained in exchange for lease obligations
Operating leases	$	-	$	-

Weighted average remaining lease term
Operating leases		-		0.08 years

Weighted average discount rate
Operating leases		-		6.5	%

Summary of Warrant Activity (Details) (Parenthetical)

12 Months Ended

Dec. 31, 2024

$ / shares

Class of Warrant or Right [Line Items]

Number of warrants, outstanding

9,612

Number of warrants, exercised

1,271,600

^[1]

Pre-Funded Warrants [Member]

Class of Warrant or Right [Line Items]

Number of warrants, outstanding

131,500

Warrants exercise price | $ / shares

$ 0.001

December 2023 Pre-Funded Warrants [Member]

Class of Warrant or Right [Line Items]

Number of warrants, exercised

131,500

Exercise price | $ / shares

$ 0.001

December 11, 2023 Series A and Series B Warrants One [Member]

Class of Warrant or Right [Line Items]

Purchase of warrants shares

239,300

Purchase of warrants per share | $ / shares

$ 3.46

December 11, 2023 Series A and Series B Warrants Two [Member]

Class of Warrant or Right [Line Items]

Purchase of warrants shares

339,900

Purchase of warrants per share | $ / shares

$ 2.06

August 1, 2024 Series A-1 and Series B-1 Warrants [Member]

Class of Warrant or Right [Line Items]

Purchase of warrants shares

478,600

Purchase of warrants per share | $ / shares

$ 2.06

[1]	Warrants exercised exclude 131,500 December 2023 Pre-Funded Warrants exercised with an exercise price of $0.001.

Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Gross proceeds	$ 1,354,404	$ 18,114,193
Issuance costs	212,102	2,390,285
Warrant [Member]
Gross proceeds	2,514,088	966,349
Issuance costs	$ 3,408,613	$ 208,702

Accrued Expenses and Other Current Liabilities

12 Months Ended

Dec. 31, 2024

Payables and Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

Note 6 – Accrued Expenses and Other Current Liabilities

As of December 31, 2024 and 2023, accrued expenses and other current liabilities consisted of the following:

	2024		2023
	For the Years Ended
	December 31,
	2024		2023

L&F milestone payment liability	$	-	$	500,000
Payroll accrual		1,039,338		668,803
Other accrued expenses		310,942		41,969
Bonus accrual		536,500		536,500
Registration delay liability ^[1]		7,261		7,261
Total accrued expenses and other current liabilities	$	1,894,041	$	1,754,533

[1]	See Note 9 – “Stockholders’ Permanent and Temporary Equity – Effectiveness Failure” for details of the registration delay liability.

Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 12,544,318	$ 9,974,075
Stock-based compensation expense	3,155,058	3,258,463
Capitalized research and development costs	1,753,207	2,182,104
Capitalized start-up costs	781,342	1,033,504
Capitalized licensing costs	609,669	647,489
Capitalized patents	392,691	351,721
Warrants	135,319	134,341
Accrued payroll	394,406	299,487
Contributions carryforward	2,878	2,857
Operating lease liability		2,151
Deferred tax assets	19,768,888	17,886,192
Valuation allowance	(15,953,288)	(14,093,900)
Deferred tax assets	3,815,600	3,792,292
Operating lease right-of-use asset		(1,948)
In-process research and development	(4,667,259)	(4,633,535)
Fixed assets		(1,723)
Deferred tax liabilities	(4,667,259)	(4,637,206)
Deferred tax assets, net	$ (851,659)	$ (844,914)

Going Concern and Management’s Plans (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 1,530,924	$ 3,137,674
Working capital deficit	9,500,000
Net loss	9,413,435	98,297,946
Net cash used In operating activities	(7,559,697)	(8,720,819)
Accumulated deficit	$ 112,632,559	$ 103,219,124

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References + Details

Stockholders’ Permanent and Temporary Equity (Details Narrative) - USD ($)																								1 Months Ended		12 Months Ended
	Jan. 01, 2025	Nov. 05, 2024	Aug. 01, 2024	Apr. 25, 2024	Mar. 06, 2024	Dec. 11, 2023	Dec. 04, 2023	Sep. 18, 2023	Sep. 14, 2023	Sep. 08, 2023	Aug. 08, 2023	Aug. 04, 2023	Aug. 02, 2023	Jul. 26, 2023	Jun. 05, 2023	Apr. 28, 2023	Mar. 29, 2023	Feb. 28, 2023	Dec. 12, 2022	Dec. 13, 2020	Jan. 31, 2020	Apr. 18, 2019	Dec. 15, 2015	Nov. 30, 2024	Oct. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Nov. 04, 2024	Feb. 23, 2024	Dec. 30, 2023	Nov. 30, 2023	Feb. 20, 2023
Subsidiary, Sale of Stock [Line Items]
Reverse stock split				the Company effected the 2023 Reverse Split and 2024 Reverse Split, respectively.			the Company effected the 2023 Reverse Split and 2024 Reverse Split, respectively.
Common stock, shares authorized																										250,000,000	250,000,000			250,000,000	110,000,000
Common stock, par value																										$ 0.0001	$ 0.0001				$ 0.0001
Preferred stock, shares authorized																										1,000,000	1,000,000				1,000,000
Preferred stock, par value																										$ 0.0001	$ 0.0001				$ 0.0001
Number of shares issued																						114
Shares issued, value																						$ 460,000
Fair value for general and administrative expesne																										$ 7,357,559	$ 11,213,201
Payments of stock issuance costs																										588,045	2,417,095
Legal costs								$ 16,131
Proceeds from sale of equity																											18,114,193
Conversion price																$ 700.00
Deemed dividend																											32,373
Common stock exercisable upon reset of Series A warrants
Satisfaction of company liabilities																										$ 5,062,000
Stock based compensation expense																										705,567	1,192,963
Unrecognized stock-based compensation expense																										$ 321,893
Weighted average period																										1 year 3 months 18 days
Gross proceeds warrants																										$ 2,672,500
Grant of new warrants term																										5 years 4 months 24 days
Gross proceeds from issuance of common stock																										$ 1,354,404
Placement agent fees								57,980
Warrant modification costs								$ 134,591
Exercise term																										5 years 4 months 24 days
Percentage of registration delay payments																																1.50%
Interest rate																																2.00%
Accrued registration delay payments																										$ 7,261
Research and Development Expense [Member]
Subsidiary, Sale of Stock [Line Items]
Stock based compensation expense																										61,789	132,767
General and Administrative Expense [Member]
Subsidiary, Sale of Stock [Line Items]
Stock based compensation expense																										$ 643,778	$ 1,060,196
Series A Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase of common shares												247
Exercise price												$ 20.00
Series B Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise floor price reset																$ 2,450.00
July 2023 Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price								$ 47.50
December 2023 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price			$ 3.46
August 2024 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price		$ 2.06
Series A Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock, shares authorized																										8,635	8,635
Warrants to purchase of common shares																										2,465
Net proceeds from issuance of shares																										$ 8,635,000
Number of shares sold																										8,635
Conversion of shares issued																35
Conversion price																										$ 3,500.00
Conversion basis																										(a) $700.00; and (b) the lowest price of any subsequent offerings of securities at a price less than the conversion price
Deemed dividend																$ 37,000
Remaining shares with conversion floor price reset																235
Conversion of shares converted																50
Preferred stock, shares designated																										50	50
Series B Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock, shares authorized																										5,062	5,062
Shares issued, price per share																										$ 1,000
Conversion basis																										(a) $2,450.00; and (b) the lowest price of any subsequent offerings of securities at a price less than the conversion price.
Deemed dividend																$ 100,000
Preferred stock, shares designated																										5,062	5,062
Shares conversion price																										$ 3,500.00
Minimum [Member] \| Series B Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Shares conversion price																										$ 2,450.00
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued for services																										60,000	10,457
Warrants to purchase of common shares		1,637,000							20,347
Exercise price		$ 2.06
Payments of stock issuance costs									$ 208,702
Conversion price																$ 700.00
Reclassification of formerly redeemable common stock																											188
Common stock exercisable upon reset of Series A warrants																14,186
Deemed dividend																$ 1,400,000
Gross proceeds from issuance of common stock									$ 966,400
Exercise term		5 years
Financial advisor fees		$ 110,000
Non accountable fees financial advisor fees		$ 10,000
Common Stock [Member] \| December 2023 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase of common shares		818,500	239,300
Payments of stock issuance costs			$ 427,054
Legal costs			57,267
Gross proceeds from issuance of common stock		$ 1,686,110	827,978
Warrant modification costs		2,786,372	246,912
Placement agent fees			50,000
Other expenses			$ 22,875
Legal and other fees		$ 75,187
Common Stock [Member] \| Series A Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion price																$ 3,500.00
Common Stock [Member] \| Series B Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion price																$ 3,500.00
Shares issued in connection with the business combination																5,062
Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase of common shares														3,938							100	227	500			200
Exercise price		$ 3.46																				$ 4,053.00	$ 1,760.50			$ 4,025.00		$ 12.50
Exercise term																							5 years
Fair value of warrants																					$ 153,324		$ 766,384
Shares issued, price per share																										$ 1,000
Incremental fair value														$ 47,300
Exercise price								$ 47.50
Grant of new warrants term								5 years 6 months
Warrant [Member] \| Maximum [Member] \| Three Investor [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price														$ 57.75
Warrant [Member] \| Minimum [Member] \| Three Investor [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price														$ 350.00
Series A Convertible Preferred Stock [Member] \| Investor [Member]
Subsidiary, Sale of Stock [Line Items]
Reclassification of formerly redeemable common stock												150
Cash payment												$ 230,000
Series A Convertible Preferred Stock [Member] \| Maximum [Member] \| Investor [Member]
Subsidiary, Sale of Stock [Line Items]
Remaining shares before redemption												200
Pre-Funded Warrants [Member] \| Investor [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase of common shares										27,057	27,057		27,057																131,500
Exercise price										$ 0.04	$ 0.04		$ 0.04																$ 0.001
Gross proceeds warrants										$ 947	$ 947		$ 947
Warrants exercised on cashless basis																													131,481
Common Stock One [Member] \| December 2023 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued			392,000
Common Stock Two [Member] \| December 2023 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued			86,600
Exercise price			$ 3.46
Exercise term			18 months
December 2023 Common Stock Purchase Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase of common shares		339,900
August 2023 Common Stock Purchase Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase of common shares		478,600
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued															8,698
Shares issued, value															$ 1,200,000
Shares held by investors															5,651
Fair value for general and administrative expesne																											$ 1,156,778
April 2023 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase of common shares																2,465
Exercise price																$ 4,025.00
Exercise floor price reset																$ 700.00
April 2023 Offering [Member] \| Series A Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from registered offering to redeem preferred stock																$ 10,500,000
Reclassification of formerly redeemable common stock																8,400
Net carrying amount of preferred stock																$ 3,700,000
Deemed dividend																$ 6,400,000
December 2023 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase of common shares					213,800
Exercise price					$ 12.50
Gross proceeds warrants					$ 2,672,500
2022 Omnibus Equity Incentive Plan [Member] \| Subsequent Event [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares increased	282,122
2022 Omnibus Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock, shares authorized																										181,795
Available for future issuance																										177,638
Marketing Agreements [Member]
Subsidiary, Sale of Stock [Line Items]
Shares issued for services																										60,000	10,457
Prepaid expense fair value of shares																										$ 79,200	$ 574,800
Marketing Agreements [Member] \| Second Contract [Member]
Subsidiary, Sale of Stock [Line Items]
Prepaid expense fair value of shares																										48,570	30,400
Marketing Agreements [Member] \| Final Contract [Member]
Subsidiary, Sale of Stock [Line Items]
Prepaid expense fair value of shares																											$ 66,420
Marketing Agreements [Member] \| Third Contract [Member]
Subsidiary, Sale of Stock [Line Items]
Prepaid expense fair value of shares																										$ 69,000
April 2023 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued																31,473
Warrants to purchase of common shares																31,473
Proceeds from sale of equity																$ 11,000,000.0
Exercise price																$ 350.00
Payments of stock issuance costs																$ 1,184,482
Placement fee																440,620
Legal costs																455,332
Accounting and professional service costs																259,774
Other offering costs																$ 28,756
July 2023 Pre-Funded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued														9,303
Warrants to purchase of common shares														27,061
Exercise price														$ 0.04
Exercise term														5 years
July 2023 Pre-Funded Warrants [Member] \| Five Years [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price														$ 57.75
July 2023 Pre-Funded Warrants [Member] \| Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase of common shares														36,364
Exercise price														$ 57.75
Share price														$ 0.04
July 2023 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Payments of stock issuance costs														$ 523,115
Placement fee														125,943
Legal costs														236,091
Accounting and professional service costs														87,037
Other offering costs														26,744
Fair value of warrants														47,300
July 2023 Offering [Member] \| Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from sale of equity														$ 2,100,000
December 2023 Pre-Funded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued						40,000
Warrants to purchase of common shares						360,000
Exercise price						$ 0.001
December 2023 Series A Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase of common shares						400,000
Exercise price						$ 12.50
Exercise term						5 years
December 2023 Series B Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants to purchase of common shares						400,000
Exercise price						$ 12.50
Exercise term						18 months
December 2023 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from sale of equity						$ 5,000,000.0
Payments of stock issuance costs						653,514
Placement fee						299,978
Legal costs						232,336
Accounting and professional service costs						94,325
Other offering costs						$ 26,875
ATM Agreement [Member] \| At-The-Market Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Net proceeds from issuance of shares																								$ 1,350,000	$ 1,350,000
Number of shares sold																								564,495	564,495
License Agreement [Member] \| L&F Research LLC [Member]
Subsidiary, Sale of Stock [Line Items]
Share price																			$ 1,762.80	$ 1.00
Reclassification shares of common stock																			331,331
Conversion of shares issued																			188
License Agreement [Member] \| L&F Research LLC [Member] \| Waiver A [Member]
Subsidiary, Sale of Stock [Line Items]
Reclassification shares of common stock																	188
Debt forgiveness																	$ 351,579	$ 351,579
Cash payment																	648,421	$ 648,421
Reclassification shares of common stock value classified as temporary to permanent equity																	$ 331,331
License Agreement [Member] \| L&F Research LLC [Member] \| Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Reclassification shares of common stock value classified as temporary to permanent equity																				331,331
Total consideration																				$ 331
Commencement Date [Member] \| Series A Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Conversion basis																										The conversion price also resets at both 90 days and 150 days following the effectiveness of the registration of the Series A Preferred Stock (each a “Commencement Date”) to the greater of (a) $700.00; and (b) 85% of the lowest of the ten consecutive daily volume-weighted average prices commencing on, and including, each Commencement Date.

Schedule of Information Related to Stock Options (Details)	12 Months Ended
	Dec. 31, 2024 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number of Options	9,612
Options Exercisable, Weighted Average Remaining Life in Years	5 years 4 months 24 days
Options Exercisable, Number of options	6,770
Exercise Price One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price \| $ / shares	$ 152.50
Options Outstanding, Number of Options	4,157
Options Exercisable, Weighted Average Remaining Life in Years	8 years 4 months 24 days
Options Exercisable, Number of options	1,674
Exercise Price Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price \| $ / shares	$ 738.50
Options Outstanding, Number of Options	286
Options Exercisable, Weighted Average Remaining Life in Years	8 years 1 month 6 days
Options Exercisable, Number of options	96
Exercise Price Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price \| $ / shares	$ 791.00
Options Outstanding, Number of Options	38
Options Exercisable, Weighted Average Remaining Life in Years	8 years 2 months 12 days
Options Exercisable, Number of options	13
Exercise Price Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price \| $ / shares	$ 1,760.50
Options Outstanding, Number of Options	1,279
Options Exercisable, Weighted Average Remaining Life in Years	1 year 10 months 24 days
Options Exercisable, Number of options	1,279
Exercise Price Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price \| $ / shares	$ 3,965.50
Options Outstanding, Number of Options	37
Options Exercisable, Weighted Average Remaining Life in Years	7 years 6 months
Options Exercisable, Number of options	37
Exercise Price Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price \| $ / shares	$ 4,053.00
Options Outstanding, Number of Options	2,095
Options Exercisable, Weighted Average Remaining Life in Years	4 years 3 months 18 days
Options Exercisable, Number of options	2,095
Exercise Price Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price \| $ / shares	$ 5,726.00
Options Outstanding, Number of Options	1,720
Options Exercisable, Weighted Average Remaining Life in Years	6 years 4 months 24 days
Options Exercisable, Number of options	1,576

Summary of Warrant Activity (Details)

12 Months Ended

Dec. 31, 2024

USD ($)

$ / shares

Equity [Abstract]

Number of warrants, outstanding beginning balance | shares

903,320

^[1]

Weighted average exercise price, beginning balance | $ / shares

$ 123.44

^[1]

Number of warrants, granted | shares

2,115,600

Weighted average exercise price, granted | $ / shares

$ 2.38

Number of warrants, forfeited | shares

(227)

Weighted average exercise price, forfeited | $ / shares

$ 4,053.00

Number of warrants, exercised | shares

(1,271,600)

^[2]

Weighted average exercise price, exercised | $ / shares

$ 4.08

^[2]

Number of warrants, repriced - old three | shares

(239,300)

^[3]

Number of warrants, repriced - old three | $ / shares

$ 12.50

^[3]

Number of warrants, repriced - new three | shares

239,300

^[3]

Weighted average repriced price new three | $ / shares

$ 3.46

^[3]

Number of warrants, repriced - old four | shares

(339,900)

^[4]

Number of warrants, repriced - old four | $ / shares

$ 12.50

^[4]

Number of warrants, repriced - new four | shares

339,900

^[4]

Weighted average repriced price new four | $ / shares

$ 2.06

^[4]

Number of warrants, repriced - old five | shares

(478,600)

^[5]

Number of warrants, repriced - old five | $ / shares

$ 3.46

^[5]

Number of warrants, repriced - new five | shares

478,600

^[5]

Weighted average repriced price new five | $ / shares

$ 2.06

^[5]

Number of warrants, outstanding ending balance | shares

1,747,093

Weighted average exercise price, ending balance | $ / shares

$ 59.59

Weighted average remaining life in years, outstanding

5 years 21 days

Aggregate intrinsic value, ending balance | $

Number of warrants, exercisable ending balance | shares

109,893

Weighted average exercise price, Exercisable | $ / shares

$ 913.41

Weighted average remaining life in years, exercisable

3 years 4 months 2 days

Aggregate intrinsic value, exercisable | $

[1]	Warrants outstanding and exercisable exclude 131,500 Pre-Funded Warrants with an exercise price of $0.001.
[2]	Warrants exercised exclude 131,500 December 2023 Pre-Funded Warrants exercised with an exercise price of $0.001.
[3]	Warrants represent the reset of the exercise price of certain December 11, 2023 Series A and Series B warrants to purchase 239,300 shares of common stock to a price of $3.46 per share.
[4]	Warrants represent the reset of the exercise price of certain December 11, 2023 Series A and Series B warrants to purchase 339,900 shares of common stock to a price of $2.06 per share.
[5]	Warrants represent the reset of the exercise price of certain August 1, 2024 Series A-1 and Series B-1 warrants to purchase 478,600 shares of common stock to a price of $2.06 per share.

Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Dec. 31, 2024

Payables and Accruals [Abstract]

Schedule of Accrued Expenses and Other Current Liabilities

As of December 31, 2024 and 2023, accrued expenses and other current liabilities consisted of the following:

	2024		2023
	For the Years Ended
	December 31,
	2024		2023

L&F milestone payment liability	$	-	$	500,000
Payroll accrual		1,039,338		668,803
Other accrued expenses		310,942		41,969
Bonus accrual		536,500		536,500
Registration delay liability ^[1]		7,261		7,261
Total accrued expenses and other current liabilities	$	1,894,041	$	1,754,533

[1]	See Note 9 – “Stockholders’ Permanent and Temporary Equity – Effectiveness Failure” for details of the registration delay liability.

Stockholders’ Permanent and Temporary Equity (Tables)

12 Months Ended

Dec. 31, 2024

Accumulated Other Comprehensive Income (Loss) [Line Items]

Schedule of Stock Options Granted

The grant date fair value of stock options granted during the years ended December 31, 2024 and December 31, 2023 was determined using the Black Scholes method, with the following assumptions used:

Schedule of Stock Options Granted

	For the Years Ended
	December 31,
	2024		2023

Fair value of common stock on date of grant		N/A		$152.50 - $791.00
Risk free interest rate		N/A		3.53% - 4.27	%
Expected term (years)		N/A		5.00 - 6.00
Expected volatility		N/A		120% - 123	%
Expected dividends		N/A		0.00	%

Schedule of Stock Option Activity

A summary of the option activity for the year ended December 31, 2024 is presented below:

Schedule of Stock Option Activity

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number Of			Exercise		Life		Intrinsic
	Options			Price		In Years		Value

Outstanding, January 1, 2024		10,243		$	2,218.51
Granted		-			-
Exercised		-			-
Expired		(631	)		1,760.50
Outstanding, December 31, 2024		9,612		$	2,248.58		6.3	$	-

Exercisable, December 31, 2024		6,770		$	2,991.15		5.4	$	-

Schedule of Information Related to Stock Options

The following table presents information related to stock options as of December 31, 2024:

Options Outstanding				Options Exercisable
				Weighted
		Outstanding		Average		Exercisable
Exercise		Number Of		Remaining Life		Number Of
Price		Options		In Years		Options

$	152.50		4,157		8.4		1,674
$	738.50		286		8.1		96
$	791.00		38		8.2		13
$	1,760.50		1,279		1.9		1,279
$	3,965.50		37		7.5		37
$	4,053.00		2,095		4.3		2,095
$	5,726.00		1,720		6.4		1,576
			9,612		5.4		6,770

Summary of Warrant Activity

A summary of the warrant activity for the year ended December 31, 2024 is presented below:

Summary of Warrant Activity

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number Of			Exercise		Life		Intrinsic
	Warrants			Price		In Years		Value

Outstanding, January 1, 2024 ^[1]		903,320		$	123.44
Issued		2,115,600			2.38
Forfeited		(227	)		4,053.00
Exercised ^[2]		(1,271,600	)		4.08
Repriced - Old ^[3]		(239,300	)		12.50
Repriced - New ^[3]		239,300			3.46
Repriced - Old ^[4]		(339,900	)		12.50
Repriced - New ^[4]		339,900			2.06
Repriced - Old ^[5]		(478,600	)		3.46
Repriced - New ^[5]		478,600			2.06
Outstanding, December 31, 2024		1,747,093		$	59.59		5.06	$	-

Exercisable, December 31, 2024		109,893		$	913.41		3.34	$	-

[1]	Warrants outstanding and exercisable exclude 131,500 Pre-Funded Warrants with an exercise price of $0.001.
[2]	Warrants exercised exclude 131,500 December 2023 Pre-Funded Warrants exercised with an exercise price of $0.001.
[3]	Warrants represent the reset of the exercise price of certain December 11, 2023 Series A and Series B warrants to purchase 239,300 shares of common stock to a price of $3.46 per share.
[4]	Warrants represent the reset of the exercise price of certain December 11, 2023 Series A and Series B warrants to purchase 339,900 shares of common stock to a price of $2.06 per share.
[5]	Warrants represent the reset of the exercise price of certain August 1, 2024 Series A-1 and Series B-1 warrants to purchase 478,600 shares of common stock to a price of $2.06 per share.

Schedule of Information Related to Stock Warrants

The following table presents information related to stock warrants as of December 31, 2024:

Warrants Outstanding				Warrants Exercisable
		Outstanding		Weighted Average		Exercisable
Exercise		Number Of		Remaining Life		Number Of
Price		Warrants		In Years		Warrants

$	2.06		1,637,000		-		-
$	12.50		7,000		2.47		7,000
$	47.50		20,347		4.20		20,347
$	57.75		19,965		3.52		19,965
$	350.00		27,551		3.32		27,551
$	700.00		13,944		2.95		13,944
$	1,760.50		300		0.02		100
$	2,415.00		3,651		2.95		3,651
$	4,025.00		17,335		2.95		17,335
			1,747,093		3.34		109,893

Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Schedule of Issuance Date Fair Value of Stock Warrants

The issuance date fair value of stock warrants issued during the years ended December 31, 2024 and 2023 was determined using the Black Scholes method, with the following assumptions used:

	For the Years Ended
	December 31,
	2024		2023

Fair value of common stock on date of grant	$2.54 - $3.46		$47.50 - $350.00
Risk free interest rate	3.62% - 4.62	%	3.51% - 4.42%
Expected term (years)	0.6 - 5.3 years		5 years
Expected volatility	87% - 111	%	121% - 123%
Expected dividends	N/A		N/A

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Schedule of Stock Option Activity (Details)	12 Months Ended
Schedule of Stock Option Activity (Details)	Dec. 31, 2024 USD ($) $ / shares shares
Equity [Abstract]
Number of Options, Outstanding beginning balance \| shares	10,243
Weighted Average Exercise Price, Outstanding beginning balance \| $ / shares	$ 2,218.51
Number of Options, Granted \| shares
Weighted Average Exercise Price, Granted \| $ / shares
Number of Options, Exercised \| shares
Weighted Average Exercise Price, Exercised \| $ / shares
Number of Options, Expired \| shares	(631)
Weighted Average Exercise Price, Expired \| $ / shares	$ 1,760.50
Number of Options, Outstanding ending balance \| shares	9,612
Weighted Average Exercise Price, Outstanding ending balance \| $ / shares	$ 2,248.58
Weighted Average Remaining Life in years, Outstanding	6 years 3 months 18 days
Aggregate Intrinsic Value, Outstanding \| $
Number of Options, Exercisable \| shares	6,770
Weighted Average Exercise Price, Exercisable \| $ / shares	$ 2,991.15
Weighted Average Remaining Life in years, Exercisable	5 years 4 months 24 days
Aggregate Intrinsic Value, Exercisable \| $

Intangible Assets and Goodwill

12 Months Ended

Dec. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets and Goodwill

Note 4 – Intangible Assets and Goodwill

Goodwill and in-process research and development (“IPR&D”) were recorded in connection with the business combination. This IPR&D originally represented the current fair value of the IPR&D assets acquired. IPR&D recorded for book purposes is considered an indefinite-lived intangible asset until the completion or the abandonment of the research and development efforts.

Management reviewed the goodwill and IPR&D for impairment in accordance with its accounting policies. As a result of the Company’s analysis, during the year ended December 31, 2023, the Company fully impaired its $11.9 million of goodwill and also recorded an $81.4 million impairment charge for its other indefinite-lived intangible assets, namely the IPR&D. There was no impairment for the year ended December 31, 2024.

Consolidated Statements of Changes in Stockholders' Equity - USD ($)

Preferred Stock [Member]

Series A Preferred Stock [Member]

Preferred Stock [Member]

Series B Preferred Stock [Member]

Common Stock [Member]

Treasury Stock, Common [Member]

AOCI Attributable to Parent [Member]

Retained Earnings [Member]

Total

Balance at Dec. 31, 2022

$ 1

$ 3

$ 104,584,170

$ (4,921,178)

$ 99,662,997

Balance, shares at Dec. 31, 2022

8,635

5,062

25,760

Reclassification of formerly redeemable common stock

331,331

Reclassification of formerly redeemable common stock, shares

188

Issuance of common stock pursuant to vendor agreements

671,621

671,620

Issuance of common stock pursuant to vendor agreements, shares

10,457

Registration costs associated with preferred stock issuance

(5,500)

Registered equity offerings

^[1]

$ 8

15,723,900

15,723,908

Registered equity offerings, shares

^[1]

80,776

Redemption of Series A Preferred Stock

$ (1)

(10,295,048)

(10,295,049)

Redemption of Series A Preferred Stock, shares

(8,550)

Conversion of Series A Preferred Stock into common stock

Conversion of series A preferred stock into common stock, shares

(35)

Shares issued as consideration for extension of lock-up period

$ 1

1,156,777

1,156,778

Shares issued as consideration for extension of lock-up period, shares

8,698

Treasury stock acquired, at cost

$ (7,168)

(7,168)

Treasury stock acquired, at cost, shares

(7)

Warrant modification

181,891

Exercise of pre-funded warrants

$ 26

1,100

1,126

Exercise of pre-funded warrants, shares

255,557

Warrant inducement offer - exercise proceeds

^[2]

$ 2

757,644

757,647

Warrant inducement offer - exercise proceeds, shares

^[2]

20,346

Round up share adjustment due to reverse split

Round up share adjustment due to reverse split, shares

3,380

Stock-based compensation

1,192,963

Net loss

(98,297,946)

Balance at Dec. 31, 2023

$ 1

$ 40

$ (7,168)

114,300,849

(103,219,124)

11,074,598

Balance, shares at Dec. 31, 2023

5,062

405,212

(7)

Issuance of common stock pursuant to vendor agreements

$ 6

196,764

196,770

Issuance of common stock pursuant to vendor agreements, shares

60,000

Warrant modification

3,033,284

Exercise of pre-funded warrants

$ 13

(13)

Exercise of pre-funded warrants, shares

131,481

Warrant inducement offer - exercise proceeds

^[3]

$ 106

(894,631)

(894,525)

Warrant inducement offer - exercise proceeds, shares

^[3]

1,057,800

Round up share adjustment due to reverse split

$ 8

(8)

Round up share adjustment due to reverse split, shares

75,410

Stock-based compensation

705,567

Net loss

(9,413,435)

Exercise of warrants

$ 21

2,672,479

2,672,500

Exercise of warrants, shares

213,800

At the market stock issuance

^[4]

$ 57

1,142,245

1,142,302

At the market stock issuance [4], shares

^[4]

564,495

Shelf registration equity issuance costs

(614)

Balance at Dec. 31, 2024

$ 1

$ 251

$ (7,168)

$ 121,155,922

$ (112,632,559)

$ 8,516,447

Balance, shares at Dec. 31, 2024

5,062

2,508,198

(7)

[1]	Includes gross proceeds of $18,114,193 less issuance costs of $2,390,285
[2]	Includes gross proceeds of $966,349 less issuance costs of $208,702
[3]	Includes gross proceeds of $2,514,088 less issuance costs of $3,408,613
[4]	Includes gross proceeds of $1,354,404 less issuance costs of $212,102

Subsequent Events (Details Narrative) - Subsequent Event [Member] $ / shares in Units, $ in Millions	Mar. 07, 2025 USD ($) $ / shares shares
Subsequent Event [Line Items]
Gross proceeds \| $	$ 2.0
Financial advisor fees	6.50%
Investor [Member]
Subsequent Event [Line Items]
Warrants to purchase common shares \| shares	957,200
Investor [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Stock, per share \| $ / shares	$ 2.06
Investor [Member] \| Minimum [Member]
Subsequent Event [Line Items]
Stock, per share \| $ / shares	$ 1.00
March 2025 Pre Funded Warrants [Member]
Subsequent Event [Line Items]
Warrant purchase \| shares	2,105,265
Stock, per share \| $ / shares	$ 0.0001
March 2025 Common Warrants [Member]
Subsequent Event [Line Items]
Warrant purchase \| shares	2,105,265
Exercise price \| shares	0.9499
Stock, per share \| $ / shares	$ 1.00

Commitments and Contingencies (Details Narrative)																5 Months Ended	12 Months Ended				120 Months Ended
Commitments and Contingencies (Details Narrative)	Jan. 09, 2025 USD ($)	Jul. 01, 2024 USD ($)	Jun. 30, 2024 USD ($)	Jan. 30, 2024 USD ($)	Jan. 15, 2024 USD ($)	Mar. 29, 2023 USD ($)	Feb. 28, 2023 USD ($)	Dec. 23, 2022 USD ($)	Aug. 26, 2022 USD ($)	Mar. 07, 2022 USD ($)	Jan. 31, 2020 USD ($) shares	Jan. 09, 2020 USD ($)	Apr. 18, 2019 USD ($) $ / shares shares	Jan. 18, 2019 USD ($) ft²	Dec. 15, 2015 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 15, 2025 USD ($)	Nov. 05, 2024 $ / shares	Nov. 04, 2024 $ / shares	Jul. 26, 2023 shares
Loss Contingencies [Line Items]
Invoices from a vendor		$ 162,800	$ 992,176													$ 268,972
Accrued interest																$ 1,894,041	$ 1,894,041	$ 1,754,533
License agreements up front cash payment													$ 346,321		$ 200,000
Aggregate milestone cash payments												$ 1,000,000	$ 22,500,000		21,500,000				$ 500,000	$ 1,500,000
Second license agreement milestone															$ 2,500,000
Cash payment exercise price withheld												351,579
Aggregate milestone cash payments, description													the first milestone payment of $200,000 is triggered by the submission of an investigational new drug application for the first indication of a therapeutic licensed product). ZyVersa is required to pay sales royalties to InflamaCORE between 5% and 10%, which expire upon the latest of: (a) expiration of the last-to-expire of a patent or (b) expiration of regulatory exclusivity, as defined in the agreement. ZyVersa is required to pay sales royalties to the University of Miami between 3% and 6%.
Number of stock issued \| shares													114
Grant date fair value													$ 460,000
Number of operating lease square feet \| ft²														3,500
Lease cost														$ 89,000
Operating lease rent expense														$ 497,000			$ 170,022	$ 154,841
Lease Commitment [Member]
Loss Contingencies [Line Items]
Operating lease rent expense					$ 112,064
Lease Commitment [Member] \| Subsequent Event [Member]
Loss Contingencies [Line Items]
Operating lease rent expense	$ 120,819
License Agreement [Member] \| L&F Research LLC [Member]
Loss Contingencies [Line Items]
Aggregate milestone cash payments								$ 1,500,000	$ 1,500,000	$ 1,500,000
Aggregate milestone cash payments, description							the Company and L&F executed an Amendment and Restatement Agreement that waived L&F’s right to terminate the L&F License Agreement or any other remedies, for non-payment of the First Milestone Payment, until (a) March 31, 2023 as to $1,000,000 of such milestone payments (“Waiver A”) and (b) January 31, 2024 as to $500,000 of milestone payments (“Waiver B”).
License Agreement [Member] \| L&F Research LLC [Member] \| Waiver A [Member]
Loss Contingencies [Line Items]
Debt forgiveness						$ 351,579	$ 351,579
Cash payment						$ 648,421	$ 648,421
Maturity date							Mar. 31, 2023
License Agreement [Member] \| L&F Research LLC [Member] \| Waiver B [Member]
Loss Contingencies [Line Items]
Cash payment				$ 500,000			$ 500,000
Maturity date							Jan. 31, 2024
Net proceeds from issuance of equity capital							$ 30,000,000
Phase 1/2 Milestone [Member]
Loss Contingencies [Line Items]
Aggregate milestone cash payments												500,000
First Anniversary Milestone [Member]
Loss Contingencies [Line Items]
Aggregate milestone cash payments												$ 500,000
Warrant [Member]
Loss Contingencies [Line Items]
Warrants to purchase of common stock \| shares											100		227		500	200	200							3,938
Exercise price per share \| $ / shares													$ 4,053.00		$ 1,760.50	$ 4,025.00	$ 4,025.00					$ 3.46	$ 12.50
Grant date fair value											$ 153,324				$ 766,384
Warrant exercisable period															5 years
Issue date fair value													$ 815,822
Warrant One [Member]
Loss Contingencies [Line Items]
Warrants to purchase of common stock \| shares													341		200
Grant date fair value																					$ 306,411
Five Year Warrant [Member]
Loss Contingencies [Line Items]
Warrants to purchase of common stock \| shares													568
Minimum [Member]
Loss Contingencies [Line Items]
Percentage of product sales															5.00%
Maximum [Member]
Loss Contingencies [Line Items]
Percentage of product sales															10.00%
Accrued Expenses and Other Current Liabilities [Member]
Loss Contingencies [Line Items]
Accrued interest																$ 268,972	$ 268,972
Interest claim																$ 924,627	$ 924,627

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
Income Taxes (Details Narrative) - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Net operating loss carry forwards, federal	$ 51,987,494	$ 41,465,440
Net operating loss carry forwards, state	37,444,050	30,035,239
Income tax, interest or penalties	$ 0	$ 0

Consolidated Balance Sheets - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Current Assets:
Cash	$ 1,530,924	$ 3,137,674
Prepaid expenses and other current assets	184,873	215,459
Total Current Assets	1,715,797	3,353,133
Equipment, net		6,933
In-process research and development	18,647,903	18,647,903
Vendor deposit	178,476	98,476
Deferred offering costs	57,238
Operating lease right-of-use asset		7,839
Total Assets	20,599,414	22,114,284
Current Liabilities:
Accounts payable	9,337,267	8,431,583
Accrued expenses and other current liabilities	1,894,041	1,754,533
Operating lease liability		8,656
Total Current Liabilities	11,231,308	10,194,772
Deferred tax liability	851,659	844,914
Total Liabilities	12,082,967	11,039,686
Commitments and Contingencies (Note 8)
Stockholders’ Equity:
Common stock, $0.0001 par value, 250,000,000 shares authorized; 2,508,198 and 405,212 shares issued at December 31, 2024 and 2023, respectively, and 2,508,191 and 402,205 shares outstanding as of December 31, 2024 and 2023	251	40
Additional paid-in-capital	121,155,922	114,300,849
Accumulated deficit	(112,632,559)	(103,219,124)
Treasury stock, at cost, 7 shares at December 31, 2024 and 2023	(7,168)	(7,168)
Total Stockholders’ Equity	8,516,447	11,074,598
Total Liabilities and Stockholders’ Equity	20,599,414	22,114,284
Series A Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock value
Series B Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock value	$ 1	$ 1

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Operating Expenses:
Research and development	$ 1,779,275	$ 3,207,573
General and administrative	7,357,559	11,213,201
Impairment of in-process research and development		81,438,426
Impairment of goodwill		11,895,033
Total Operating Expenses	9,136,834	107,754,233
Loss From Operations	(9,136,834)	(107,754,233)
Other (Income) Expense:
Interest (income) expense	269,856	(457)
Pre-Tax Loss	(9,406,690)	(107,753,776)
Income tax (provision) benefit	(6,745)	9,455,830
Net Loss	(9,413,435)	(98,297,946)
Deemed dividend to preferred stockholders		(7,948,209)
Net Loss Attributable to Common Stockholders	$ (9,413,435)	$ (106,246,155)
Net Loss Per Share
Basic	$ (8.48)	$ (1,089.70)
Diluted	$ (8.48)	$ (1,089.70)
Weighted Average Number of Common Shares Outstanding
Basic	1,110,033	97,500
Diluted	1,110,033	97,500

Schedule of Issuance Date Fair Value of Stock Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Warrant [Member]
Expected term (years)		5 years
Minimum [Member]
Risk free interest rate		3.53%
Expected term (years)		5 years
Expected volatility		120.00%
Minimum [Member] \| Warrant [Member]
Fair value of common stock on date of grant	$ 2.54	$ 47.50
Risk free interest rate	3.62%	3.51%
Expected term (years)	7 months 6 days
Expected volatility	87.00%	121.00%
Maximum [Member]
Risk free interest rate		4.27%
Expected term (years)		6 years
Expected volatility		123.00%
Maximum [Member] \| Warrant [Member]
Fair value of common stock on date of grant	$ 3.46	$ 350.00
Risk free interest rate	4.62%	4.42%
Expected term (years)	5 years 3 months 18 days
Expected volatility	111.00%	123.00%

Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)

Dec. 31, 2024

Dec. 31, 2023

Payables and Accruals [Abstract]

L&F milestone payment liability

$ 500,000

Payroll accrual

1,039,338

668,803

Other accrued expenses

310,942

41,969

Bonus accrual

536,500

Registration delay liability

^[1]

7,261

Total accrued expenses and other current liabilities

$ 1,894,041

$ 1,754,533

[1]	See Note 9 – “Stockholders’ Permanent and Temporary Equity – Effectiveness Failure” for details of the registration delay liability.

- Definition

Amount of liabilities classified as other.

+ References + Details

Going Concern and Management’s Plans

12 Months Ended

Dec. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Going Concern and Management’s Plans

Note 2 – Going Concern and Management’s Plans

As of December 31, 2024, the Company had cash of approximately $1.5 million and a working capital deficit of approximately $9.5 million. During the year ended December 31, 2024, the Company incurred a net loss of approximately $9.4 million and used cash in operations of approximately $7.6 million. The Company has an accumulated deficit of approximately $112.6 million as of December 31, 2024.

The Company has incurred losses each year since its inception and has a net working capital deficiency as of December 31, 2024. Based upon the cash on hand as of the date the financials were issued, the Company expects that the cash it currently has available will not fund its operations for 12 months from the issuance date of the financial statements. As a result, the Company will be required to raise additional funds through equity or debt financing, and there can be no assurance that it will be successful in securing additional capital. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance date of these financial statements.

The Company has not yet achieved profitability and expects to continue to incur cash outflows from operations. It is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The Company’s cash flow needs include the planned costs to operate its business, including amounts required to fund research and development, working capital, and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings. We intend to raise additional capital in the future to fund operations. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustment that might become necessary should the Company be unable to continue as a going concern.

Business Organization, Nature of Operations and Risks and Uncertainties

12 Months Ended

Dec. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business Organization, Nature of Operations and Risks and Uncertainties

Note 1 – Business Organization, Nature of Operations and Risks and Uncertainties

Organization and Operations

Larkspur Health Acquisition Corp. (“Larkspur”), a blank-check special purpose acquisition company, was incorporated in Delaware on March 17, 2021. On December 12, 2022, Larkspur consummated the Business Combination with ZyVersa Therapeutics, Inc. (“Predecessor”) which was incorporated in the State of Florida on March 11, 2014 as Variant Pharmaceuticals, Inc. On the date of consummation of the Business Combination, Larkspur (“New Parent”) changed its name to ZyVersa Therapeutics, Inc. and the Predecessor changed its name to ZyVersa Therapeutics Operating, Inc. (the “Operating Company”) after merging with a subsidiary of the New Parent, with the Operating Company being the surviving entity, which resulted in it being incorporated in Delaware and it being a wholly-owned subsidiary of the New Parent (collectively the “Successor”). References to the “Company” or “ZyVersa” refer to the Successor for the Successor period from December 13, 2022 to December 31, 2022 and to the Predecessor for the Predecessor period from January 1, 2022 to December 12, 2022.

ZyVersa is a clinical stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. Our mission is to develop drugs that optimize health outcomes and improve patients’ quality of life.

Risks and Uncertainties

On March 10, 2023, Silicon Valley Bank (“SVB”) was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (“FDIC”) was appointed as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. A statement by the Department of the Treasury, the Federal Reserve and the FDIC stated that all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts. The standard deposit insurance amount is up to $250,000 per depositor, per insured bank, for each account ownership category. Although we do not have any funds deposited with the aforementioned banks, we regularly maintain cash balances with other financial institutions in excess of the FDIC insurance limit. A failure of a depository institution to return deposits could impact access to our cash or cash equivalents and could adversely impact our operating liquidity and financial performance.

Stockholders’ Permanent and Temporary Equity

12 Months Ended

Dec. 31, 2024

Equity [Abstract]

Stockholders’ Permanent and Temporary Equity

Note 9 – Stockholders’ Permanent and Temporary Equity

Reverse Stock Split

On December 4, 2023 and April 25, 2024, the Company effected the 2023 Reverse Split and 2024 Reverse Split, respectively. See Note 3 – Summary of Significant Accounting Policies, Basis of Presentation and Principles of Consolidation for additional details.

Authorized Capital

The Company was authorized to issue 110,000,000 shares of common stock, par value of $0.0001 per share, and 1,000,000 shares of preferred stock, par value $0.0001 per share. The holders of the common stock are entitled to one vote per share.

Effective November 30, 2023, the Company amended its certificate of incorporation to increase the authorized shares of common stock from 110,000,000 to 250,000,000.

Equity Incentive Plans

Predecessor 2014 Equity Incentive Plan

On December 12, 2022, in connection with the consummation of the Business Combination, the Predecessor approved the amendment to the 2014 Plan (the “2014 Plan Amendment”). The 2014 Plan Amendment provides, among other things, that upon consummation of the Business Combination, no further increases in the shares of common stock reserved and available for issuance under the 2014 Plan shall occur and no new awards shall be made under the 2014 Plan.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

2022 Omnibus Equity Incentive Plan

The Company is authorized to issue awards under the 2022 Omnibus Equity Incentive Plan (the “2022 Plan”), as amended on October 31, 2023 and October 29, 2024. Under the 2022 Plan, 181,795 shares of common stock are authorized for issuance as of December 31, 2024. The number of shares of common stock available for issuance under the 2022 Plan shall automatically increase on the first trading day of January each calendar year during the term of the 2022 Plan, beginning with calendar year 2023, by an amount equal to four percent (4%) of the total number of shares of common stock outstanding on the last trading day in December of the immediately preceding calendar year. The 2022 Plan provides for the issuance of incentive stock options, non-statutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock and restricted stock units to employees, directors and consultants of the Company and its affiliates. The 2022 Plan requires the exercise price of stock options to be not less than the fair value of the Company’s common stock on the date of grant. As of December 31, 2024, there were 177,638 shares available for future issuance under the 2022 Plan.

On January 1, 2025, the total number of shares under the 2022 Omnibus Equity Incentive Plan automatically increased to 282,122.

Common Stock

On June 5, 2023, the Company issued 8,698 shares of common stock valued at $1.2 million to certain investors in a private placement (including to certain members of the Company’s sponsor) in exchange for increasing the duration of their lockup period until July 31, 2023 with respect to an aggregate of 5,651 shares of common stock underlying all securities of the Company held by such investors. The $1,156,778 fair value of the common stock issued was recorded in general and administrative expense in the Statement of Operations during the year ended December 31, 2023.

During the year ended December 31, 2023, the Company entered into marketing agreements with three vendors in which the Company issued an aggregate of 10,457 shares of common stock and cash in exchange for marketing services. The fair value of the common stock was established as a prepaid expense and the Company is recognizing $574,800 of the expense over the six month term of one of the contracts, $30,400 of the expense over the twelve month term of the second contract, and $66,420 over the six month term of the final contract.

During the year ended December 31, 2024, the Company entered into marketing agreements with three vendors in which the Company issued an aggregate of 60,000 shares of common stock in exchange for marketing services. The fair value of the common stock was established as a prepaid expense and the Company is recognizing $79,200 of the expense over the six month term of one of the contracts, $48,570 of the expense over the six month term of the second contract, and $69,000 of the expense over the three month term of the third contract.

Registered Equity Offerings

On April 28, 2023, the Company completed a registered offering of 31,473 shares of common stock and warrants to purchase 31,473 shares of common stock for gross proceeds of $11.0 million (the “April 2023 Offering”). Each share of common stock was sold together with a five-year warrant to purchase one share of common stock at an exercise price of $350.00 per share, which was exercisable upon issuance. The Company determined that the warrant should be equity-classified, primarily because it is indexed to the Company’s own stock and it met the requirements for equity classification. Accordingly, because both the common stock and the warrant are equity-classified, it wasn’t necessary to allocate the proceeds or the issuance costs to the respective securities. Total issuance costs were $1,184,482 including $440,620 placement fees, $455,332 of legal fees, $259,774 of accounting and professional service costs related to the offering, and $28,756 of other costs.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

On July 26, 2023, the Company completed a registered offering of 9,303 shares of common stock, pre-funded warrants (the “July 2023 Pre-Funded Warrants”) to purchase 27,061 shares of common stock and common warrants (the “July 2023 Warrants”) to purchase 36,364 shares of common stock at a combined public offering price of $57.75 per share (less $0.04 for each July 2023 Pre-Funded Warrant) which resulted in gross proceeds of $2.1 million (the “July 2023 Offering”). The July Pre-Funded Warrants are exercisable immediately, may be exercised at any time until all July 2023 Pre-Funded Warrants are exercised in full, and have an exercise price of $0.04 per share. The July 2023 Warrants are exercisable immediately for a term of five years and have an exercise price of $57.75 per share. The Company determined that both warrants should be equity-classified, primarily because they are indexed to the Company’s own stock and they met the requirements for equity classification. Accordingly, because the common stock and both warrants are equity-classified, it wasn’t necessary to allocate the proceeds or the issuance costs to the respective securities. Total issuance costs were $523,115 including $125,943 of placement fees, $236,091 of legal fees, $87,037 of accounting and professional service costs related to the offering, $26,744 of other costs, and $47,300 incremental fair value of the modified warrants as compared to the original warrants (see Stock Warrants below).

On December 11, 2023, the Company completed a registered offering of 40,000 shares of common stock, pre-funded warrants (the “December 2023 Pre-Funded Warrants”) to purchase 360,000 shares of common stock, Series A common warrants (the “December 2023 Series A Warrants”) to purchase 400,000 shares of common stock, and Series B common warrants (the “December 2023 Series B Warrants”) to purchase 400,000 shares of common stock at a combined public offering price of $12.50 per share (less $0.001 for each December 2023 Pre-Funded Warrant) which resulted in gross proceeds of $5.0 million (the “December 2023 Offering”). The December 2023 Pre-Funded Warrants are exercisable immediately, may be exercised at any time until all Pre-Funded Warrants are exercised in full, and have an exercise price of $0.001 per share. The December 2023 Series A Warrants are exercisable immediately for a term of five years and have an exercise price of $12.50 per share. The December 2023 Series B Warrants are exercisable immediately for a term of 18-months and have an exercise price of $12.50 per share. The Company determined that all warrants should be equity-classified, primarily because they are indexed to the Company’s own stock and they met the requirements for equity classification. Accordingly, because the common stock and warrants are equity-classified, it wasn’t necessary to allocate the proceeds or the issuance costs to the respective securities. Total issuance costs were $653,514 including $299,978 of placement fees, $232,336 of legal fees, $94,325 of accounting and professional service costs related to the offering, and $26,875 of other costs.

At-The-Market Offering

In October and November 2024, the Company received approximately $1.35 million in gross proceeds from the sale of 564,495 shares of its common stock pursuant to its ATM Agreement with A.G.P. for its “at-the-market” facility.

Redeemable Common Stock and Put Option

On December 13, 2020 (the “Effective Date”), in connection with the L&F Note Agreement (see Note 5 – Note Receivable for details), the Predecessor and L&F entered into an agreement to provide L&F with a put option to cause the Company to purchase up to 331,331 shares of Predecessor common stock (“Put Shares”) at a price of $1.00 per share (“Put Option”). The put option expires at the earlier of (A) the date that the L&F Note is repaid in full; or (B) the fifth (5th) anniversary of the Effective Date. The parties agreed that, in the event of an exercise by L&F, in lieu of paying L&F for the Put Shares, the Company shall reduce the amount of the receivable then owed by L&F to the Company under the L&F Note Agreement. The Put Option was sold to L&F for total consideration of $331, which was recorded within additional paid-in capital.

On December 12, 2022, the Company closed on the Business Combination whereby the 331,331 shares of Predecessor common stock subject to the Put Option were exchanged for 188 shares of Successor common stock at a price of $1762.80 per share. The put option has the practical effect of making the underlying shares of Successor common stock redeemable. As a result, they were classified as temporary equity on the December 31, 2022 balance sheet.

On March 29, 2023, the Company forgave $351,579 in aggregate principal amount outstanding on the L&F Note and paid $648,421 of cash to L&F, thus meeting the conditions of Waiver A. L&F’s put option expired upon meeting the Waiver A conditions, which resulted in a reclassification of 188 shares of Successor common stock and $331,331 classified as temporary equity to permanent equity.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Preferred Stock

Series A Preferred Stock Financing

In connection with the Business Combination, the Company sold 8,635 shares of Series A Preferred Stock and five-year warrants to purchase 2,465 shares of common stock at an exercise price of $4,025.00 per share (the “PIPE Warrants”), to certain purchasers at a price of $1,000 per share for net proceeds of $8,635,000 (the “PIPE” financing).

The Series A Preferred Stock is convertible, at the option of the holder, at any time into a number of shares of common stock equal to the face value divided by the conversion price then in effect (initially $3,500.00). In addition, for five years following the issuance of the Series A Preferred Stock, the conversion price is automatically adjusted to the greater of (a) $700.00; and (b) the lowest price of any subsequent offerings of securities at a price less than the conversion price.

The conversion price also resets at both 90 days and 150 days following the effectiveness of the registration of the Series A Preferred Stock (each a “Commencement Date”) to the greater of (a) $700.00; and (b) 85% of the lowest of the ten consecutive daily volume-weighted average prices commencing on, and including, each Commencement Date.

The Series A Preferred stockholders have no voting rights and dividends will only be paid on an as-converted basis when, and if paid to common stockholders. In the event of any liquidation, dissolution or winding up of the Company, each Series A Preferred stockholder shall be entitled to be paid out of the assets of the Company legally available for distribution, the stated value of their holdings, plus any accrued and unpaid dividends. The balance of any proceeds shall be distributed to Series A Preferred stockholders on an as-converted basis pari passu with the Company common stockholders.

The Series A Preferred Stock is not redeemable at the election of the holder and, therefore, it is classified as permanent equity. However, subject to the holder’s right to elect to convert, the Company has the right to redeem the Series A Preferred Stock anytime at 120% of the face value. The Company determined that the embedded conversion options were clearly and closely related to the preferred stock host and, therefore, the embedded conversion options need not be bifurcated. However, if the conversion price is reset in connection with a subsequent issuance of securities, the Company will need to assess the accounting for the price reset. Due to the Company’s adoption of ASU 2020-06 on January 1, 2021, it wasn’t necessary to assess the embedded conversion options for a beneficial conversion feature.

On or about April 28, 2023, cash proceeds from the April 2023 Offering in the amount of $10.5 million were used to redeem 8,400 shares of Series A Preferred Stock. The loss on the extinguishment of preferred stock is accounted for in a manner similar to the treatment of dividends paid on preferred stock. The loss on extinguishment is calculated as the difference between (a) the fair value of the negotiated $10.5 million of cash transferred to the holders of the Series A Preferred Stock (which also settled the Company’s obligation to make Effectiveness Failure payments (See Note 9 – “Stockholders’ Permanent and Temporary Equity – Effectiveness Failure” for details of Effectiveness Failure)), and (b) the $3.7 million net carrying amount of the Series A Preferred Stock. Accordingly, the redemption resulted in the recognition of a $6.4 million deemed dividend for the purposes of calculating the Company’s loss per common share. Because the Company has an accumulated deficit, both the debit and the credit associated with the dividend are to additional paid-in-capital, so there is no balance sheet effect.

On August 3, 2023, the Company entered into a redemption agreement and release with an investor which resulted in the Company, on August 4, 2023, redeeming 150 of the 200 remaining shares of Series A Convertible Preferred Stock and warrants to purchase 247 shares of common stock at an exercise price of $20.00 per share for a cash payment of $230,000. The Company recognized an $32,373 deemed dividend during the year ended December 31, 2023, as a result of the extinguishment accounting associated with the redemption.

As a result of the April 2023 Offering, (a) the exercise price of the Series A Warrants to purchase 2,465 shares of common stock at an exercise price of $4,025.00 per share that were issued to participants in the original PIPE financing had the exercise price reset to its floor price of $700.00 per share, while becoming exercisable for 14,186 shares of common stock (which resulted in the recognition of a $1.4 million deemed dividend); and (b) the remaining 235 shares of Series A Preferred Stock had their $3,500.00 original conversion price reset to the floor conversion price of $700.00 per share of common stock (which resulted in the recognition of a $37,000 deemed dividend).

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Following the triggering of the down round provision, the holders of 35 shares of Series A Preferred Stock converted into 50 shares of common stock at the new conversion price of $700.00 per share.

Preferred Series B Issuance

In connection with the Business Combination, the Company issued 5,062 shares of Series B Preferred Stock to certain vendors that provided services to the Company at a price of $1,000 per share in exchange for the satisfaction of $5,062,000 of Company liabilities.

The Series B Preferred Stock is convertible, at the option of the holder, at any time into a number of shares of common stock equal to the face value divided by the conversion price then in effect (initially $3,500.00). In addition, for five years following the issuance of the Series B Preferred Stock, the conversion price is automatically adjusted to the greater of (a) $2,450.00; and (b) the lowest price of any subsequent offerings of securities at a price less than the conversion price.

The conversion price also resets at 150 days following the effectiveness of the registration of the Series B Preferred Stock (each a “Commencement Date”) to the greater of (a) $2,450.00; and (b) the lowest of the five consecutive daily volume-weighted average prices commencing on, and including, the Commencement Date.

The Series B Preferred stockholders have no voting rights and dividends will only be paid on an as-converted basis when, and if paid to common stockholders. In the event of any liquidation, dissolution or winding up of the Company each Series B Preferred stockholder shall be entitled to be paid out of the assets of the Company legally available for distribution, the stated value of their holdings, plus any accrued and unpaid dividends. The balance of any proceeds shall be distributed to Series B Preferred stockholders on an as-converted basis pari passu with the Company common stockholders.

The Series B Preferred Stock is not redeemable and, therefore, it is classified as permanent equity. The Company determined that the embedded conversion options were clearly and closely related to the preferred stock host and, therefore, the embedded conversion options need not be bifurcated. However, if the conversion price is reset in connection with a subsequent issuance of securities, the Company will need to assess the accounting for the price reset. Due to the Company’s adoption of ASU 2020-06 on January 1, 2021, it wasn’t necessary to assess the embedded conversion options for a beneficial conversion feature.

As a result of the April 2023 Offering, the $3,500.00 original conversion price of the 5,062 shares of Series B Preferred Stock issued in connection with the Business Combination reset to its floor price of $2,450.00 per share of common stock (which resulted in the recognition of a $0.1 million deemed dividend).

Stock-Based Compensation

For the year ended December 31, 2024, the Company recorded stock-based compensation expense of $705,567 (of which, $61,789 was included in research and development and $643,778 was included in general and administrative expense) related to options issued to employees and consultants. As of December 31, 2024, there was $321,893 of unrecognized stock-based compensation expense, which the Company expects to recognize over a weighted average period of 1.3 years.

For the year ended December 31, 2023, the Company recorded stock-based compensation expense of $1,192,963 (of which, $132,767 was included in research and development and $1,060,196 was included in general and administrative expense) related to options issued to employees and consultants.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Stock Options

The grant date fair value of stock options granted during the years ended December 31, 2024 and December 31, 2023 was determined using the Black Scholes method, with the following assumptions used:

Schedule of Stock Options Granted

	For the Years Ended
	December 31,
	2024		2023

Fair value of common stock on date of grant		N/A		$152.50 - $791.00
Risk free interest rate		N/A		3.53% - 4.27	%
Expected term (years)		N/A		5.00 - 6.00
Expected volatility		N/A		120% - 123	%
Expected dividends		N/A		0.00	%

A summary of the option activity for the year ended December 31, 2024 is presented below:

Schedule of Stock Option Activity

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number Of			Exercise		Life		Intrinsic
	Options			Price		In Years		Value

Outstanding, January 1, 2024		10,243		$	2,218.51
Granted		-			-
Exercised		-			-
Expired		(631	)		1,760.50
Outstanding, December 31, 2024		9,612		$	2,248.58		6.3	$	-

Exercisable, December 31, 2024		6,770		$	2,991.15		5.4	$	-

The following table presents information related to stock options as of December 31, 2024:

Options Outstanding				Options Exercisable
				Weighted
		Outstanding		Average		Exercisable
Exercise		Number Of		Remaining Life		Number Of
Price		Options		In Years		Options

$	152.50		4,157		8.4		1,674
$	738.50		286		8.1		96
$	791.00		38		8.2		13
$	1,760.50		1,279		1.9		1,279
$	3,965.50		37		7.5		37
$	4,053.00		2,095		4.3		2,095
$	5,726.00		1,720		6.4		1,576
			9,612		5.4		6,770

Stock Warrants

On July 26, 2023, in connection with the July 2023 Offering (see Registered Equity Offerings above), the Company amended the exercise price of certain warrants to purchase 3,938 shares of common stock for three investors from $350.00 to $57.75 per share and the expiration date was modified from April 28, 2028 to July 28, 2028. The $47,300 incremental fair value of the modified warrants as compared to the original warrants was recognized as an additional issuance cost of the July 2023 Offering.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

On August 2, August 8 and September 8, 2023, a July 2023 Offering investor exercised pre-funded warrants to purchase an aggregate of 27,057 shares of common stock at an exercise price of $0.04 per share for total proceeds of $947.

Between September 13 and September 18, 2023, the Company initiated a limited time program, which at the election of the warrant holder, would permit them to immediately exercise their July 2023 Warrants at a reduced exercise price of $47.50 per share and they would also be granted new 5.5-year warrants to purchase an equal number of shares of common stock at an exercise price of $47.50 per share. The new warrants are not exercisable for the first six months. Under the program, warrants to purchase an aggregate of 20,347 shares of common stock were exercised on September 14, 2023 for gross proceeds of $966,400 less total issuance costs of $208,702. Issuance costs include placement agent fees of $57,980, legal costs of $16,131, and warrant modification costs of $134,591. Because the modification represented a short-term inducement, modification accounting was only performed on the warrants that were actually exercised under the program. The Company recognized the $134,591 modification date incremental value of the modified warrants and additional warrants issued as compared to the original warrants, as an issuance cost of the warrant exercise.

Between February 26, 2024 and March 6, 2024, investors in the registered offering completed on December 11, 2023 (the “December 2023 Offering”) exercised warrants to purchase 213,800 shares of common stock at an exercise price of $12.50 per share for total proceeds of $2,672,500.

Between January 17 and February 23, 2024, a December 2023 Offering investor exercised pre-funded warrants to purchase 131,500 shares of common stock on a cashless basis and received 131,481 shares of common stock at an exercise price of $0.001 per share.

On August 1, 2024, the Company initiated a limited time program, which was immediately accepted by the warrant holder, that permitted the holder to exercise its December 2023 Offering warrants at a reduced exercise price of $3.46 per share and granted new warrants to purchase up to (i) 392,000 shares of common stock which became exercisable upon stockholder approval with an exercise term of five years and (ii) 86,600 shares of common stock which became exercisable upon stockholder approval with an exercise term of 18 months. The Company received stockholder approval for the warrants on October 29, 2024 and the warrants have an exercise price of $3.46 per share. Under the program, the warrant holder submitted an exercise notice and the related aggregate cash exercise price to purchase 239,300 shares of common stock on August 1, 2024 for gross proceeds of $827,978 less issuance costs of $427,054. Issuance costs included placement agent fees of $50,000, placement agent legal fees of $50,000, Company legal fees of $57,267, other expenses of $22,875 and warrant modification costs of $246,912. Because the modification represented a short-term inducement, modification accounting was only performed on the warrants that were actually exercised under the program. The Company recognized the $246,912 modification date incremental value of the modified warrants and additional warrants issued as compared to the original warrants, as an issuance cost of the warrant exercise.

On November 5, 2024, the Company initiated a limited time program, which was immediately accepted by the warrant holder, that permitted the holder to exercise 339,900 of its December 2023 and 478,600 of its August 2024 Common Stock Purchase warrants at a reduced exercise price of $2.06 per share from $12.50 and $3.46 per share, respectively. New warrants were granted to purchase 1,637,000 shares of common stock at an exercise price of $2.06 per share with an exercise term of 5 years from stockholder approval. Under the program, the warrant holders submitted exercise notices and the related aggregate cash exercise price to purchase an aggregate of 818,500 shares of common stock on November 5, 2024 for gross proceeds of $1,686,110. Issuance costs include financial advisor fees of $110,000, reimbursement to the financial advisor for non-accountable fees of $10,000, legal and other fees of $75,187, and warrant modification costs of $2,786,372. Because the Existing Warrants and the shares issued in connection with their exercise were equity classified, and because the Reload Warrants are equity classified, and because the Existing Warrant modification was in connection with an equity financing transaction to raise capital, the Company recognized the $2,786,372 modification date incremental value of the modified warrants and additional warrants issued as compared to the original warrants, as an issuance cost of the warrant exercise.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The issuance date fair value of stock warrants issued during the years ended December 31, 2024 and 2023 was determined using the Black Scholes method, with the following assumptions used:

	For the Years Ended
	December 31,
	2024		2023

Fair value of common stock on date of grant	$2.54 - $3.46		$47.50 - $350.00
Risk free interest rate	3.62% - 4.62	%	3.51% - 4.42%
Expected term (years)	0.6 - 5.3 years		5 years
Expected volatility	87% - 111	%	121% - 123%
Expected dividends	N/A		N/A

A summary of the warrant activity for the year ended December 31, 2024 is presented below:

Summary of Warrant Activity

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number Of			Exercise		Life		Intrinsic
	Warrants			Price		In Years		Value

Outstanding, January 1, 2024 ^[1]		903,320		$	123.44
Issued		2,115,600			2.38
Forfeited		(227	)		4,053.00
Exercised ^[2]		(1,271,600	)		4.08
Repriced - Old ^[3]		(239,300	)		12.50
Repriced - New ^[3]		239,300			3.46
Repriced - Old ^[4]		(339,900	)		12.50
Repriced - New ^[4]		339,900			2.06
Repriced - Old ^[5]		(478,600	)		3.46
Repriced - New ^[5]		478,600			2.06
Outstanding, December 31, 2024		1,747,093		$	59.59		5.06	$	-

Exercisable, December 31, 2024		109,893		$	913.41		3.34	$	-

[1]	Warrants outstanding and exercisable exclude 131,500 Pre-Funded Warrants with an exercise price of $0.001.
[2]	Warrants exercised exclude 131,500 December 2023 Pre-Funded Warrants exercised with an exercise price of $0.001.
[3]	Warrants represent the reset of the exercise price of certain December 11, 2023 Series A and Series B warrants to purchase 239,300 shares of common stock to a price of $3.46 per share.
[4]	Warrants represent the reset of the exercise price of certain December 11, 2023 Series A and Series B warrants to purchase 339,900 shares of common stock to a price of $2.06 per share.
[5]	Warrants represent the reset of the exercise price of certain August 1, 2024 Series A-1 and Series B-1 warrants to purchase 478,600 shares of common stock to a price of $2.06 per share.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The following table presents information related to stock warrants as of December 31, 2024:

Warrants Outstanding				Warrants Exercisable
		Outstanding		Weighted Average		Exercisable
Exercise		Number Of		Remaining Life		Number Of
Price		Warrants		In Years		Warrants

$	2.06		1,637,000		-		-
$	12.50		7,000		2.47		7,000
$	47.50		20,347		4.20		20,347
$	57.75		19,965		3.52		19,965
$	350.00		27,551		3.32		27,551
$	700.00		13,944		2.95		13,944
$	1,760.50		300		0.02		100
$	2,415.00		3,651		2.95		3,651
$	4,025.00		17,335		2.95		17,335
			1,747,093		3.34		109,893

Effectiveness Failure

In connection with the Business Combination, the Company conducted the Series A Preferred Stock Financing. On or about February 20, 2023, the Company failed to have the SEC declare a registration statement effective (the “Effectiveness Failure”) which covered the Series A Preferred Stock registrable securities within the time period prescribed by the Securities Purchase Agreement (the “SPA”). The SPA entitles the investors to receive registration delay payments (“Registration Delay Payments”) equal to 1.5% of each investor’s purchase price on the date of the Effectiveness Failure and every thirty days thereafter that the Effectiveness Failure persists. Failure to make the Registration Delay Payments on a timely basis result in the accrual of interest at the rate of 2.0% per month. On April 28, 2023, the proceeds from the April 2023 Offering were used to make most of the Registration Delay Payments and redeem substantially all of the Series A Preferred Stock (see Series A Preferred Stock Financing above). As of December 31, 2024, the Company has accrued additional Registration Delay Payments of approximately $7,261 in the aggregate.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Subsequent Events

12 Months Ended

Dec. 31, 2024

Subsequent Events [Abstract]

Subsequent Events

Note 11 – Subsequent Events

The Company has evaluated subsequent events through the date the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as discussed below.

Private Placement

On March 7, 2025, the Company entered into a private placement (the “Private Placement”) with an institutional investor, pursuant to which the Company agreed to sell pre-funded warrants (the “March 2025 Pre-Funded Warrants”) to purchase 2,105,265 shares of common stock and Series A-3 common warrants (the “March 2025 Common Warrants”) to purchase 2,105,265 shares of common stock at a combined purchase price of $0.9499 which resulted in gross proceeds of $2.0 million. In addition, the Company and the investor entered into an amendment to certain November 5, 2024 common share purchase warrants to reduce the exercise price of the warrants to purchase 957,200 shares of common stock from $2.06 per share to $1.00 per share. The March 2025 Pre-Funded Warrants are exercisable immediately, may be exercised at any time until all March 2025 Pre-Funded Warrants are exercised in full, and have an exercise price of $0.0001 per share. The March 2025 Common Warrants are exercisable upon Stockholder Approval for a term of five years following stockholder approval and have an exercise price of $1.00 per share. Issuance costs include financial advisor fees of 6.5% of gross proceeds plus reimbursement of certain non-accountable and other expenses.

Pay vs Performance Disclosure - USD ($)	12 Months Ended
Pay vs Performance Disclosure - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (9,413,435)	$ (98,297,946)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Consolidated Statement of CashFlows - USD ($)	12 Months Ended
Consolidated Statement of CashFlows - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Cash Flows From Operating Activities:
Net loss	$ (9,413,435)	$ (98,297,946)
Adjustments to reconcile net loss to net cash used in operating activities:
Impairment of in-process research and development		81,438,426
Impairment of goodwill		11,895,033
Stock-based compensation	705,567	1,192,963
Issuance of common stock pursuant to vendor agreements	196,770	671,620
Shares issued as consideration for extension of lock-up period		1,156,778
Depreciation of fixed assets	6,933	10,400
Non-cash rent expense	7,839	90,532
Deferred tax provision (benefit)	6,745	(9,479,069)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	30,586	56,547
Vendor deposits	(80,000)	136,524
Deferred offering costs	97,877
Accounts payable	750,569	2,405,938
Operating lease liability	(8,656)	(100,100)
Accrued expenses and other current liabilities	139,508	101,535
Net Cash Used In Operating Activities	(7,559,697)	(8,720,819)
Cash Flows From Financing Activities:
Proceeds from issuance of common stock in public offering		18,114,193
Registration and issuance costs associated with common stock issuance	(588,045)	(2,417,095)
Redemption of Series A Preferred Stock		(10,695,611)
Purchase of treasury stock		(7,168)
Exercise of pre-funded warrants		1,126
Exercise of warrants	2,672,500
Warrant inducement offer - exercise proceeds	2,514,088	966,349
At the market issuance of stock proceeds	1,354,404
Registration and issuance costs associated with preferred stock issuance		(5,500)
Net Cash Provided By Financing Activities	5,952,947	5,956,294
Net Decrease in Cash	(1,606,750)	(2,764,525)
Cash - Beginning of Year	3,137,674	5,902,199
Cash - End of Year	1,530,924	3,137,674
Non-Cash Investing and Financing Activities:
Reclassification of formerly redeemable common stock		331,331
Accounts payable for deferred offering costs	17,075	44,892
Warrant modification - incremental value		181,891
Warrant inducement offer - incremental value	$ 3,033,284	$ 134,591

Intangible Assets and Goodwill (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill impairment charges	$ 0	$ 11,900,000
Other indefinite lived intangible assets		$ 81,400,000

Summary of Significant Accounting Policies (Details Narrative)			12 Months Ended
	Apr. 25, 2024	Dec. 04, 2023	Dec. 31, 2024 USD ($) Segment	Dec. 31, 2023 USD ($)
Product Information [Line Items]
Reverse stock split	the Company effected a reverse stock split of its common stock at a ratio of 1-for-10 (the “2024 Reverse Split”). Upon the effectiveness of the 2024 Reverse Split, every 10 issued shares of common stock were reclassified and combined into one share of common stock	the Company effected a reverse stock split of its common stock at a ratio of 1-for-35 (the “2023 Reverse Split”). Upon the effectiveness of the 2023 Reverse Split, every 35 issued shares of common stock were reclassified and combined into one share of common stock
Cash equivalents			$ 0	$ 0
Estimated useful life			5 years
Equipment			$ 52,000	52,000
Accumulated depreciation			52,000	45,067
Depreciation of fixed assets			$ 6,933	$ 10,400
Number of operating and reporting segment \| Segment			1
Accounts Payable [Member] \| Customer Concentration Risk [Member] \| One Vendor Accounted [Member]
Product Information [Line Items]
Concentration risk percentage			56.00%	59.00%

Commitments and Contingencies

12 Months Ended

Dec. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 8 – Commitments and Contingencies

Litigations, Claims and Assessments

In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records contingent liabilities resulting from such claims, if any, when a loss is assessed to be probable and the amount of the loss is reasonably estimable.

Disputed Vendor Invoices

On June 30, 2024 and July 1, 2024, the Company received two invoices from a vendor in the amounts of $992,176 and $162,800, respectively. The June 30, 2024 invoice represents retroactive interest on invoices going back to September 30, 2022. The July 1, 2024 invoice included miscellaneous unsupported charges performed over the past several years. On August 1, 2024, ZyVersa management sent the vendor a letter disputing the interest and unsupported charges and has requested the vendor to rescind each of them. The Company received additional invoices, dated July 31, 2024 thru December 31, 2024, which included $268,972 of interest for those same periods. Although the Company has requested the vendor to rescind the retroactive interest on invoices, the Company believes that in accordance with the agreement, the vendor can legally charge the Company interest from the point they were notified. As such, the Company included the calculated interest from July 1, 2024 to December 31, 2024 of $268,972 within accrued expenses and other current liabilities on the consolidated balance sheet at December 31, 2024. The vendor also updated certain interest calculations such that, at December 31, 2024, the vendors interest claim that has not been accrued by the Company is $924,627.

License Agreements

L&F Research LLC

The Company entered into a License Agreement with L&F Research LLC (“L&F Research”) effective December 15, 2015, as amended (the “L&F License Agreement”) pursuant to which L&F granted the Company an exclusive royalty-bearing, worldwide, sublicensable license under the patent and intellectual property rights and know-how specific to and for the development and commercialization of VAR 200, for the treatment, inhibition or prevention of kidney disease in humans and symptoms thereof, including focal segmental glomerulosclerosis. The term of the license agreement shall commence on the effective date and, unless earlier terminated in accordance with the terms of the agreement, continue until the expiration of the last-to-expire of all royalty payment obligations of licensee.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The license agreement contains an up-front cash payment of $200,000 (paid and recognized as research and development expense in 2015), $21.5 million in aggregate milestone cash payments (the Company will recognize expense associated with the milestone cash payments when such milestones become probable of being achieved; $1,500,000 of expense was recognized during 2020 (of which, $500,000 was originally due and payable in 2021) related to the U.S. Food and Drug Administration (“FDA”) acceptance of an investigational new drug application as well as commencement of Phase 2a clinical trials; the next milestone of $2,500,000 is earned upon a positive end of Phase 2 meeting with the FDA), royalties ranging from 5%-10% on sales of the product when it comes to market (the Company will recognize royalty expense if and when sales occur; none recognized to-date) and warrants to purchase an aggregate of 500 shares of common stock at an exercise price of $1,760.50 per share that were issued in 2015 with a grant date fair value of $766,384 that become exercisable for a period of five years from the date of achievement of specified milestones (a warrant to purchase 200 shares of common stock was exercisable upon its issuance in 2015 and, accordingly, the Company recognized its grant date fair value of $306,411 during 2015 as research and development expense with a corresponding credit to additional paid-in capital and was subsequently exercised on December 13, 2020; the Company will recognize expense associated with the remaining warrants when it is probable that the associated performance conditions will be achieved; a warrant to purchase 100 shares of common stock became exercisable in January 2020 upon the FDA acceptance of an investigational new drug application for a compound or product, as defined, at which time the Company recognized expense equal to the grant date fair value of $153,324; warrants to purchase 200 shares of common stock were not exercisable as of December 31, 2024 as the milestones were not achieved). For the consideration above that has yet to have been expensed or paid, the Company will recognize associated expense when such items become both probable of being achieved and such value is estimable.

On January 9, 2020, an amendment was entered into for the license agreement that provided for the following amendments: (i) partially extended the timing of payment of $1,000,000 of milestone cash payments associated with the successful completion of Phase 1 clinical trials ($500,000 payable upon commencement of Phase 2a clinical trials (the “Phase 1/2 Milestone”) and $500,000 payable upon the one year anniversary of the Phase 1/2 Milestone (“First Anniversary Milestone”); and (ii) upon the condition that L&F exercises its warrant upon achievement of the Phase 1/2 Milestone, the $351,579 exercise price is to be withheld from the cash payment due to L&F in connection with the Phase ½ Milestone. See Note 5 – Note Receivable for further details about the promissory note agreement entered into upon the exercise of warrants by L&F and Note 9 – Permanent and Temporary Stockholders’ Equity – Redeemable Common Stock and Put Option for discussion about the put option agreement entered into by the Company and L&F in connection with the L&F Note Agreement.

On March 7, 2022, August 26, 2022 and December 23, 2022, the Company and L&F executed a Waiver Agreement that waives L&F’s right to terminate the license agreement or any other remedies, for non-payment of the $1,500,000 of milestone payments, collectively through March 31, 2023. All other terms of the license agreement remain in effect.

On February 28, 2023, the Company and L&F executed an Amendment and Restatement Agreement that waived L&F’s right to terminate the L&F License Agreement or any other remedies, for non-payment of the First Milestone Payment, until (a) March 31, 2023 as to $1,000,000 of such milestone payments (“Waiver A”) and (b) January 31, 2024 as to $500,000 of milestone payments (“Waiver B”). Waiver A was contingent upon (i) forgiveness by the Company of $351,579 in aggregate principal amount outstanding under a certain convertible note, and (ii) a cash payment by the Company to L&F in the amount of $648,421, on or before March 31, 2023. Waiver B is contingent upon a cash payment by the Company to L&F in the amount of $500,000 on or before the earlier of (x) January 31, 2024, and (y) ten business days from the date that the Company receives net proceeds of at least $30,000,000 from the issuance of new equity capital. All other terms of the L&F License remain in effect. See Note 5 – Note Receivable for further details around the promissory note agreement entered into upon the exercise of warrants by L&F and Note 9 – Stockholders’ Permanent and Temporary Equity – Redeemable Common Stock and Put Option for discussion about the put option agreement entered into by the Company and L&F in connection with the L&F Note Agreement.

On March 29, 2023, the Company paid the $648,421 of cash to L&F, thus meeting the conditions of Waiver A, which also had the effect of canceling the Note Receivable and the Put Option.

On January 30, 2024, the Company paid $500,000 of cash to L&F, thus meeting the conditions of Waiver B.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

InflamaCORE

On April 18, 2019, the Company entered into a license agreement with InflamaCORE, LLC (“InflamaCORE”) whereby InflamaCORE agreed to grant the Company an exclusive license to the InflamaCORE Program Technology for the development and commercialization of IC 100, for the treatment of inflammation. The term of the license agreement shall commence on the effective date and, unless earlier terminated in accordance with the terms of the agreement, continue until the expiration of the last-to-expire of all royalty payment obligations of licensee. In conjunction with this license agreement, InflamaCORE entered into an agreement with the University of Miami to aggregate all of the intellectual property and technology developed by InflamaCORE scientists, who are all employees of the University of Miami, under the InflamaCORE umbrella. The term of the agreement shall commence on the effective date and shall remain in effect until the later of (a) the date on which all issued patents and filed patent applications within the patent rights have expired or been abandoned and no royalties are due or (b) twenty (20) years, unless earlier terminated in accordance with the terms of the agreement. The two agreements were executed with the understanding that ZyVersa will further develop the intellectual property and technology under the license agreement.

In consideration for the license, the Company agreed to pay an up-front fee to InflamaCORE in the amount of $346,321 to cover the patent cost reimbursement to the University of Miami. InflamaCORE is also entitled to six milestone payments totaling $22,500,000 (the first milestone payment of $200,000 is triggered by the submission of an investigational new drug application for the first indication of a therapeutic licensed product). ZyVersa is required to pay sales royalties to InflamaCORE between 5% and 10%, which expire upon the latest of: (a) expiration of the last-to-expire of a patent or (b) expiration of regulatory exclusivity, as defined in the agreement. ZyVersa is required to pay sales royalties to the University of Miami between 3% and 6%. Finally, InflamaCORE received five-year warrants to purchase an aggregate of 568 shares of common stock, of which, a warrant to purchase 227 shares of common stock, with an issue date fair value of $815,822, which was recorded as research and development expenses, was issued at the execution of the agreement at an exercise price of $4,053.00 per share and the remaining warrants to purchase 341 shares of common stock are to be issued at a price per share equal to the fair value of the common stock at the time of issuance upon the satisfaction of certain milestones, unless the Company closes an initial public offering (“IPO”), defined as the initial public offering of the Predecessor’s Common Stock or other equity securities, at which point all warrants will be issued. If the Company completes its IPO within the three-year period immediately prior to the expiration date, the expiration date shall automatically be extended until the third anniversary of the effective date of the Company’s IPO. The Company determined that the Business Combination didn’t meet the definition of an IPO. The University of Miami also received 114 shares of common stock, with a grant date fair value of $460,000, which was recorded as research and development expenses, under the agreement. As of December 31, 2024, the Successor did not pay or owe any royalties, the performance milestones associated with the cash payments and issuance of warrants were not achieved and the Company did not accrue for any payments or issue the remaining warrants associated with the license agreement.

Operating Leases

On January 18, 2019, the Company entered into a lease agreement for approximately 3,500 square feet of office space in Weston, Florida for a term of five years. Under the lease agreement, the annual base rent, which excludes the Company’s share of taxes and operating costs, was approximately $89,000 for the first year and has increased approximately 3% every year thereafter for a total base rent lease commitment of approximately $497,000. On January 15, 2024, the Company extended the lease for an additional year for a total base rent lease commitment of $112,064. On January 9, 2025, the Company extended the lease for an additional year for a total base rent lease commitment of approximately $120,819. The Company used the short-term lease practical expedient which permits the Company to not capitalize leases with a term equal to or less than 12 months.

The Company recognized rent expense in connection with its operating lease for the year ended December 31, 2024 and 2023 of $170,022 and $154,841, respectively.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

A summary of the Company’s right-of-use assets and liabilities is as follows:

	2024		2023
	For the Years Ended
	December 31,
	2024		2023

Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows used in operating activities	$	8,656	$	100,099

Right-of-use assets obtained in exchange for lease obligations
Operating leases	$	-	$	-

Weighted average remaining lease term
Operating leases		-		0.08 years

Weighted average discount rate
Operating leases		-		6.5	%

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive:

	2024		2023
	For the Years Ended
	December 31,
	2024		2023

Warrants ^[1]		1,747,093		903,274
Options		9,612		10,243
Series A convertible preferred stock		72		72
Series B convertible preferred stock		2,067		2,067
Total potentially dilutive shares		1,758,844		915,657

[1]

Schedule of Information Related to Stock Warrants (Details) - $ / shares

12 Months Ended

Dec. 31, 2024

Dec. 31, 2023

^[1]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants Outstanding, Number of Warrants

1,747,093

903,320

Warrants Exercisable, Number of Warrants

109,893

Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants Outstanding, Number of Warrants

1,747,093

Warrants Exercisable, Number of Warrants

109,893

Warrants Exercisable, Weighted Average Remaining Life in years

3 years 4 months 2 days

Exercise Price One [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted Outstanding, Exercise Price

$ 2.06

Warrants Outstanding, Number of Warrants

1,637,000

Warrants Exercisable, Number of Warrants

Exercise Price Two [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted Outstanding, Exercise Price

$ 12.50

Warrants Outstanding, Number of Warrants

7,000

Warrants Exercisable, Number of Warrants

7,000

Warrants Exercisable, Weighted Average Remaining Life in years

2 years 5 months 19 days

Exercise Price Three [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted Outstanding, Exercise Price

$ 47.50

Warrants Outstanding, Number of Warrants

20,347

Warrants Exercisable, Number of Warrants

20,347

Warrants Exercisable, Weighted Average Remaining Life in years

4 years 2 months 12 days

Exercise Price Four [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted Outstanding, Exercise Price

$ 57.75

Warrants Outstanding, Number of Warrants

19,965

Warrants Exercisable, Number of Warrants

19,965

Warrants Exercisable, Weighted Average Remaining Life in years

3 years 6 months 7 days

Exercise Price Five [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted Outstanding, Exercise Price

$ 350.00

Warrants Outstanding, Number of Warrants

27,551

Warrants Exercisable, Number of Warrants

27,551

Warrants Exercisable, Weighted Average Remaining Life in years

3 years 3 months 25 days

Exercise Price Six [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted Outstanding, Exercise Price

$ 700.00

Warrants Outstanding, Number of Warrants

13,944

Warrants Exercisable, Number of Warrants

13,944

Warrants Exercisable, Weighted Average Remaining Life in years

2 years 11 months 12 days

Exercise Price Seven [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted Outstanding, Exercise Price

$ 1,760.50

Warrants Outstanding, Number of Warrants

300

Warrants Exercisable, Number of Warrants

100

Warrants Exercisable, Weighted Average Remaining Life in years

7 days

Exercise Price Eight [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted Outstanding, Exercise Price

$ 2,415.00

Warrants Outstanding, Number of Warrants

3,651

Warrants Exercisable, Number of Warrants

3,651

Warrants Exercisable, Weighted Average Remaining Life in years

2 years 11 months 12 days

Exercise Price Nine [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Weighted Outstanding, Exercise Price

$ 4,025.00

Warrants Outstanding, Number of Warrants

17,335

Warrants Exercisable, Number of Warrants

17,335

Warrants Exercisable, Weighted Average Remaining Life in years

2 years 11 months 12 days

[1]	Warrants outstanding and exercisable exclude 131,500 Pre-Funded Warrants with an exercise price of $0.001.

Insider Trading Arrangements	12 Months Ended
Insider Trading Arrangements	Dec. 31, 2024
Insider Trading Arrangements [Line Items]
No Insider Trading Flag	true

Income Taxes

12 Months Ended

Dec. 31, 2024

Income Tax Disclosure [Abstract]

Income Taxes

Note 7 – Income Taxes

The Company is subject to United States federal and state income taxes.

The provision for income taxes consists of the following (benefits) provisions:

Schedule of Provision for Income Taxes

	2024			2023
	For the Years Ended
	December 31,
	2024			2023

Current tax benefit:
Federal	$	-		$	-
State		-			23,240
Current tax benefit		-			23,240

Deferred tax benefit:
Federal		(1,688,265	)		(19,104,800	)
State		(164,376	)		(4,468,170	)
Deferred tax benefit		(1,852,641	)		(23,572,970	)
Change in valuation allowance		1,859,386			14,093,900
Provision for income taxes	$	6,745		$	(9,455,830	)

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The provision for income taxes differs from the Federal statutory rate as follows:

	2024			2023
	For the Years Ended
	December 31,
	2024			2023

Federal statutory rate		21.0	%		21.0	%
State tax rate, net of federal benefit		3.0	%		3.8	%
Permanent items		0.0	%		(2.8	)%
Stock-based compensation		(3.2	)%		0.0	%
Effect of change in state rate		0.2	%		(0.1	)%
Prior period adjustments and other		(1.3	)%		0.0	%
Change in valuation allowance		(19.8	)%		(13.1	)%
Other		0.0	%		0.0	%
Effective income tax rate		(0.1	)%		8.8	%

Deferred tax assets and liabilities consist of the following:

	2024			2023
	As of December 31,
	2024			2023

Net operating loss carryforwards	$	12,544,318		$	9,974,075
Stock-based compensation expense		3,155,058			3,258,463
Capitalized research and development costs		1,753,207			2,182,104
Capitalized start-up costs		781,342			1,033,504
Capitalized licensing costs		609,669			647,489
Capitalized patents		392,691			351,721
Warrants		135,319			134,341
Accrued payroll		394,406			299,487
Contributions carryforward		2,878			2,857
Operating lease liability		-			2,151
Deferred tax assets		19,768,888			17,886,192
Valuation allowance		(15,953,288	)		(14,093,900	)
Deferred tax assets		3,815,600			3,792,292

Operating lease right-of-use asset		-			(1,948	)
In-process research and development		(4,667,259	)		(4,633,535	)
Fixed assets		-			(1,723	)
Deferred tax liabilities		(4,667,259	)		(4,637,206	)

Deferred tax assets, net	$	(851,659	)	$	(844,914	)

On December 31, 2024 and 2023, the Company had approximately $51,987,494 and $41,465,440 Federal net loss (“NOL”) carryforwards, respectively, and $37,444,050 and $30,035,239 of State NOLs, respectively.

Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements as of December 31, 2024 and 2023. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.

ZYVERSA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

No tax audits were commenced or were in process during the years ended December 31, 2024 and 2023 and no tax related interest or penalties were incurred during those years. The Company’s tax returns beginning with the year ended December 31, 2021 remain subject to examination.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Schedule of Anti-dilutive Securities Excluded From Calculation of Diluted Net Loss Per Share (Details) (Parenthetical) - shares	Dec. 31, 2024	Dec. 31, 2023
InflamaCORE, LlC License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase common shares	342	342